

---

## Medical Policy



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

**Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.**

---

**\*Current Policy Effective Date: 1/1/24**  
(See policy history boxes for previous effective dates)

### **Title: Implantable Cardioverter Defibrillator (ICD), Including Subcutaneous ICDs And Substernal ICDs**

---

#### **Description/Background**

##### **VENTRICULAR ARRHYTHMIA AND SUDDEN CARDIAC DEATH**

The risk of ventricular arrhythmia and sudden cardiac death (SCD) may be significantly increased in various cardiac conditions such as individuals with ischemic cardiomyopathy, particularly when associated with reduced left ventricular ejection fraction (LVEF) and prior myocardial infarction; nonischemic dilated cardiomyopathy with reduced LVEF; hypertrophic cardiomyopathy who have additional risk factors; congenital heart disease, particularly with recurrent syncope; and cardiac ion channelopathies.

##### **Treatment**

An implantable cardioverter defibrillator (ICD) is a device designed to monitor a patient's heart rate, recognize ventricular fibrillation (VF) or ventricular tachycardia (VT), and deliver an electric shock to terminate these arrhythmias to reduce the risk of sudden death.

Indications for ICD implantation can be broadly subdivided into 1) secondary prevention, i.e., their use in patients who have experienced a potentially life-threatening episode of ventricular tachyarrhythmia (VT) (near sudden cardiac death); and 2) primary prevention, i.e., their use in patients who are considered at high risk for sudden cardiac death but who have not yet experienced life-threatening VT or ventricular fibrillation (VF).

The standard ICD involves placement of a generator in the subcutaneous tissue of the chest wall. Transvenous leads are attached to the generator and threaded intravenously into the endocardium. The leads sense and transmit information on cardiac rhythm to the generator, which analyzes the rhythm information and produces an electrical ventricular fibrillation shock when a malignant arrhythmia is recognized.

A subcutaneous ICD (S-ICD®) has also been developed. This device does not use transvenous leads and thus avoids the need for venous access and complications associated

with the venous leads. Rather, the S-ICD® uses a subcutaneous electrode that is implanted adjacent to the left sternum. The electrodes sense the cardiac rhythm and deliver countershocks through the subcutaneous tissue of the chest wall.

Another extravascular ICD, the substernal ICD, is being studied for its safety and efficacy. This device, like the S-ICD® above, is a device that does not use transvenous leads. Instead, this device uses a lead that is placed under the sternum, outside of the heart and veins.

Several automatic ICDs are approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. FDA-labeled indications generally include patients who have experienced life-threatening VT associated with cardiac arrest or VT associated with hemodynamic compromise and resistance to pharmacologic treatment. In addition, devices typically have approval in the secondary prevention setting in patients with previous myocardial infarction (MI) and reduced ejection fraction.

---

## Regulatory Status

### Transvenous Implantable Cardioverter Defibrillators

The U.S. Food and Drug Administration (FDA) has approved a large number of implantable cardioverter defibrillators (ICDs) through the premarket approval (PMA) process (FDA product code: LWS). A 2014 review of the FDA approvals of cardiac implantable devices reported that between 1979 and 2012, the FDA approved 19 ICDs (7 pulse generators, 3 leads, and 9 combined systems) through new PMA applications.<sup>1</sup> Many originally approved ICDs have undergone multiple supplemental applications. A summary of some currently available ICDs is provided in Table 1 (not an exhaustive list):

---

## Background

In April 2021, Medtronic issued a recall of the Evera, Viva, Brava, Claria, Amplia, Compia, and Visia ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) due to an unexpected and rapid decrease in battery life.<sup>2</sup> The decrease in battery life is caused by a short circuit and will cause some devices to produce a "Recommended Replacement Time" warning earlier than expected. Some devices may progress from this warning to full battery depletion within as little as 1 day. The device may stop functioning if the user does not respond to the first warning. In August 2022, Medtronic issued a recall of the Cobalt XT, Cobalt, and Crome ICDs and CRT-Ds because of risk that the devices may issue a short circuit alert and deliver a reduced energy electric shock instead of delivering a second phase of high voltage therapy.<sup>3</sup> The reduced energy electrical shock may fail to correct an arrhythmia or may cause an irregular heartbeat. The FDA identified both events as Class I recalls, the most serious type of recall, indicating a situation in which use of these devices may cause serious injuries or death.

### Subcutaneous ICDs

In September 2012, the Subcutaneous Implantable Defibrillator (S-ICD®) System (Cameron Health, San Clemente, CA; acquired by Boston Scientific, Marlborough, MA) was approved by the FDA through the PMA process for the treatment of life-threatening ventricular

tachyarrhythmias in patients who do not have symptomatic bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with ant-tachycardia pacing (Table 1).

In March 2015, the Emblem S-ICD™ (Boston Scientific), which is smaller and longer lasting than the original S-ICD, was approved by the FDA through the PMA supplement process.

In February 2021, Boston Scientific issued a recall of the Emblem S-ICD because of increased risk of device fractures. The FDA designated the recall a Class I event, the most serious type of recall, indicating a situation in which there is a reasonable probability that the use of the device may cause serious injuries or death.<sup>4</sup>

**Table 1: Implantable Cardioverter Defibrillators With FDA Approval**

Device	Manufacturer	Original PMA Approval Date
<b>Transvenous</b>		
Ellipse™/Fortify Assura™ Family (originally: Cadence Tiered Therapy Defibrillation System)	St. Jude Medical	Jul 1993
Current® Plus ICD (originally: Cadence Tiered Therapy Defibrillation System)	St. Jude Medical	Jul 1993
Dynagen™, Inogen™, Origen™, and Teligen® Family (originally: Ventak, Vitality, Cofient family)	Boston Scientific	Jan 1998
Evera™ Family (originally: Virtuosos/Entrust/Maximo/Intrinsic/Marquis family)	Medtronic	Dec 1998
<b>Subcutaneous</b>		
Subcutaneous Implantable Defibrillator System (S-ICD™)	Cameron Health; acquired by Boston Scientific	Sep 2012

FDA: Food and Drug Administration; PMA: premarket application

### **Substernal Implantable Cardioverter Defibrillators**

There are currently no FDA approved substernal ICDs.

## **Medical Policy Statement**

The safety and effectiveness of a transvenous automatic implantable cardioverter defibrillator (ICD) have been established. It may be considered a useful therapeutic option for patients who meet selection criteria.

The safety and effectiveness of a *subcutaneous* automatic implantable cardioverter defibrillator (ICD) have been established. It may be considered a useful therapeutic option for patients who meet selection criteria.

The use of a substernal implantable cardioverter defibrillator is considered experimental/investigational. The safety and effectiveness on clinical outcomes have not been definitively demonstrated.

---

## Inclusionary and Exclusionary Guidelines

### Transvenous automatic implantable cardioverter defibrillators

#### I. Adults

The use of the automatic implantable cardioverter defibrillator (AICD) may be considered **established** in individuals who meet the following criteria:

##### *Primary Prevention*

##### Inclusions:

- Ischemic cardiomyopathy with New York Heart Association (NYHA) functional Class II or Class III symptoms, a history of myocardial infarction at least 40 days before ICD treatment, and left ventricular ejection fraction of 35% or less; **or**
- Ischemic cardiomyopathy with NYHA functional Class I symptoms, a history of myocardial infarction at least 40 days before ICD treatment, and left ventricular ejection fraction of 30% or less; **or**
- Nonischemic dilated cardiomyopathy and left ventricular ejection fraction of 35% or less, after reversible causes have been excluded, and the response to optimal medical therapy has been adequately determined; **or**
- Hypertrophic cardiomyopathy (HCM) with 1 or more major risk factors for sudden cardiac death (history of premature HCM-related sudden death in 1 or more first-degree relatives younger than 50 years; left ventricular hypertrophy greater than 30 mm; 1 or more runs of nonsustained ventricular tachycardia at heart rates of 120 beats per minute or greater on 24-hour Holter monitoring; prior unexplained syncope inconsistent with neurocardiogenic origin) and judged to be at high risk for sudden cardiac death by a physician experienced in the care of individuals with HCM.
- Diagnosis of any one of the following cardiac ion channelopathies\* and considered to be at high risk for sudden cardiac death.
  - Congenital long QT syndrome; or
  - Brugada syndrome; or
  - Short QT syndrome; or
  - Catecholaminergic polymorphic ventricular tachycardia
- Diagnosis of cardiac sarcoid and considered to be at high risk for sudden cardiac death as indicated given one of the following below:
  - Spontaneous sustained ventricular arrhythmias, including prior cardiac arrest, if meaningful survival of greater than 1 year is expected;
  - Left ventricular ejection fraction (LVEF) 35% or less, despite optimal medical therapy and a period of immunosuppression (if there is active inflammation), if meaningful survival of greater than 1 year is expected;
  - LVEF greater than 35%, if meaningful survival of greater than 1 year is expected;**AND**
  - syncope or near-syncope, felt to be arrhythmic in etiology OR
  - evidence of myocardial scar by cardiac MRI or positron emission tomographic (PET) scan OR
  - Inducible sustained ventricular arrhythmias (>30 seconds of monomorphic VT or polymorphic VT) or clinically relevant VF
- An indication for permanent pacemaker implantation.

\*Criteria for ICD implantation in individuals with cardiac ion channelopathies:

Individuals with cardiac ion channelopathies may have a history of a life-threatening clinical event associated with ventricular arrhythmic events such as sustained ventricular tachyarrhythmia, after reversible causes, in which case they should be considered for ICD implantation for secondary prevention, even if they do not meet criteria for primary prevention.

Criteria for ICD placement in individuals with cardiac ion channelopathies derive from results of clinical input, a 2013 consensus statement from the HRS, European Heart Rhythm Association (EHRA), and the Asia-Pacific Heart Rhythm Society on the diagnosis and management of individuals with inherited primary arrhythmia syndromes, and a report from the HRS and EHRA's Second Consensus Conference on Brugada syndrome.

Indications for consideration for ICD placement for each cardiac ion channelopathy are as follows:

- Long QT syndrome (LQTS):
  - Individuals with a diagnosis of LQTS who are survivors of cardiac arrest
  - Individuals with a diagnosis of LQTS who experience recurrent syncope while on  $\beta$ -blocker therapy.
- Brugada syndrome (BrS):
  - Individuals with a diagnosis of BrS who are survivors of cardiac arrest
  - Individuals with a diagnosis of BrS who have documented spontaneous sustained ventricular tachycardia (VT) with or without syncope
  - Individuals with a spontaneous diagnostic type 1 electrocardiogram (ECG) who have a history of syncope, seizure, or nocturnal agonal respiration judged to be likely caused by ventricular arrhythmias (after noncardiac causes have been ruled out)
  - Individuals with a diagnosis of BrS who develop ventricular fibrillation during programmed electrical stimulation.
- Catecholaminergic polymorphic ventricular tachycardia (CPVT):
  - Individuals with a diagnosis of CPVT who are survivors of cardiac arrest
  - Individuals with a diagnosis of CPVT who experience recurrent syncope or polymorphic/bidirectional VT despite optimal medical management, and/or left cardiac sympathetic denervation.
- Short QT syndrome (SQTS):
  - Individuals with a diagnosis of SQTS who are survivors of cardiac arrest
  - Individuals with a diagnosis of SQTS who are symptomatic and have documented spontaneous VT with or without syncope
  - Individuals with a diagnosis of SQTS who are asymptomatic or symptomatic and have a family history of sudden cardiac death.

NOTE: For congenital LQTS, individuals may have 1 or more clinical or historical findings other than those outlined above that could, alone or in combination, put them at higher risk for sudden cardiac death. They can include individuals with a family history of sudden cardiac death due to LQTS, infants with a diagnosis of LQTS with functional 2:1 atrioventricular block, individuals with a diagnosis of LQTS in conjunction with a diagnosis of Jervell and Lange-Nielsen syndrome or Timothy syndrome, and individuals with a diagnosis of LQTS with profound QT prolongation (>550 ms). These factors should be evaluated on an individualized basis by a clinician with expertise in LQTS when considering the need for ICD placement.

### Exclusions:

The use of the ICD for primary prevention is considered experimental/investigational in primary prevention individuals who:

- Have had an acute myocardial infarction (i.e., less than 40 days before ICD treatment);
- Have New York Heart Association (NYHA) class IV congestive heart failure (unless patient is eligible to receive a combination cardiac resynchronization therapy ICD device);
- Have had a cardiac revascularization procedure in past 3 months (coronary artery bypass graft [CABG] or percutaneous transluminal coronary angioplasty [PTCA]) or are candidates for a cardiac revascularization procedure; or
- Have noncardiac disease that would be associated with life expectancy less than 1 year.
- The use of the ICD for primary prevention is considered experimental/investigational for all other indications not meeting criteria.

### *Secondary Prevention*

#### Inclusions:

- individuals with a history of a life-threatening clinical event associated with ventricular arrhythmic events such as sustained ventricular tachyarrhythmia, after reversible causes (e.g., acute ischemia) have been excluded.

#### Exclusions:

- The use of the ICD for secondary prevention is considered experimental/investigational for all other indications not meeting criteria.

## **II. Pediatrics**

#### Inclusions:

The use of the ICD or SCD may be considered established in pediatric individuals who meet **any** of the following criteria:

- Survivors of cardiac arrest, after reversible causes have been excluded; **or**
- Symptomatic, sustained ventricular tachycardia in association with congenital heart disease in individuals who have undergone hemodynamic and electrophysiologic evaluation; **or**
- Congenital heart disease with recurrent syncope of undetermined origin in the presence of either ventricular dysfunction or inducible ventricular arrhythmias; **or**
- Hypertrophic cardiomyopathy (HCM) with 1 or more major risk factors for sudden cardiac death (history or premature HCM-related sudden death in 1 or more first-degree relatives younger than 50 years; massive left ventricular hypertrophy based on age-specific norms; prior unexplained syncope inconsistent with neurocardiogenic origin) and judged to be at high risk for sudden cardiac death by a physician experienced in the care of patients with HCM; **or**
- Diagnosis of any one of the following cardiac ion channelopathies\* (please refer to Criteria for ICD implantation in individuals with cardiac ion channelopathies for adults above) and considered to be at high risk for sudden cardiac death
  - Congenital long QT syndrome; or
  - Brugada syndrome; or
  - Short QT syndrome; or
  - Catecholaminergic polymorphic ventricular tachycardia.

Exclusions:

The use of the transvenous ICD is considered **experimental/investigational** for all other indications in pediatric patients that do not meet the criteria.

**Subcutaneous automatic implantable cardioverter defibrillators**

The use of a subcutaneous ICD may be considered **established** for adult or pediatric individuals who have an indication for Transvenous ICD implantation for primary or secondary prevention for any of the above reasons and meet **all** of the following criteria:

- Have a contraindication to a transvenous ICD due to 1 or more of the following: (1) lack of adequate vascular access; (2) compelling reason to preserve existing vascular access (i.e., need for chronic dialysis; younger individual with anticipated long-term need for ICD therapy); or (3) history of need for explantation of a transvenous ICD due to a complication, with ongoing need for ICD therapy;
- Have no indication for antibradycardia pacing;
- Do not have ventricular arrhythmias known or anticipated to respond to antitachycardia pacing;
- A high risk for infection, e.g., immunocompromised patients or those with a history of a previous transvenous infection
- History of congenital heart disease with anatomic limitations for transvenous placement of the transvenous AICD
- History of need for explantation of a transvenous ICD due to a complication, with ongoing need for ICD therapy

**Exclusions:**

- The individual has a need for cardiac pacing
- The use of subcutaneous ICD for all other indications that do not meet the above criteria.

**Substernal implantable cardioverter defibrillator**

The substernal ICD is experimental/investigational for all indications.

---

**CPT/HCPCS Level II Codes** *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure)*

**Established codes:**

33215	33216	33217	33218	33220	33223
33230	33231	33240	33241	33243	33244
33249	33262	33263	33264	33270	33271
33272	33273	93260	93261	93282	93283
93284	93287	93289	93295	93296	

**Other codes (investigational, not medically necessary, etc.):**

0571T-0578T      0614T

---

## Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

## Transvenous Implantable Cardioverter Defibrillators for Primary Prevention

### Clinical Context and Therapy Purpose

The purpose of transvenous implantable cardioverter defibrillator (T-ICD) placement is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with a high-risk of sudden cardiac death (SCD) due to ischemic cardiomyopathy , inherited cardiac ion channelopathy, or cardiac sarcoid.

The following **PICOs** were used to select literature to inform this review.

### Populations

The relevant population of interest are individuals with a high-risk of SCD due to ischemic or nonischemic cardiomyopathy , inherited cardiac ion channelopathy, or cardiac sarcoid.

### Interventions

The therapy being considered is T-ICD placement. An ICD is a device designed to monitor a patient's heart rate, recognize ventricular fibrillation (VF) or ventricular tachycardia (VT), and deliver an electric shock to terminate these arrhythmias to reduce the risk of sudden death. Patients with a high-risk of SCD due to ischemic cardiomyopathy in adulthood are actively managed by cardiologists, cardiovascular surgeons, neurologists, and primary care providers in an inpatient clinical setting.

### Comparators



Comparators of interest include medical management without ICD placement. Guideline based medical management for ischemic cardiovascular disease including antihypertensive therapy and antiarrhythmic medications.

**Outcomes**

The general outcomes of interest are overall survival (OS), morbid events, quality of life (QOL), treatment-related mortality, and treatment-related morbidity. Table 2 describes outcomes of interest related to quality of life and treatment-related morbidity for individuals at high risk of SCD due to ischemic or non-ischemic cardiomyopathy.

**Table 2. Outcomes of Interest for Individuals at High-Risk of Sudden Cardiac Death due to Ischemic Cardiomyopathy in Adulthood**

Outcomes	Details	Timing
Quality of life	Can be assessed patient reported data such as surveys and questionnaires	1 week to 5 years
Treatment-related morbidity	Can be assessed rates of adverse events, including inappropriate shock, lead failure, infection, and other complications	1 week to 5 years

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

**Primary Prevention in Adults**

Transvenous implantable cardioverter defibrillators (T-ICDs) have been evaluated for primary prevention in a number of populations considered at high risk of sudden cardiac death (SCD), including those with ischemic cardiomyopathy, nonischemic dilated cardiomyopathy (NIDCM), and hypertrophic cardiomyopathy (HCM). There is a large body of evidence, including a number of randomized clinical trials (RCTs) and systematic reviews of these trials addressing the role of ICDs for primary prevention and identifying specific populations who may benefit.

**ISCHEMIC CARDIOMYOPATHY AND NONISCHEMIC DILATED CARDIOMYOPATHY (NIDCM)**

**Randomized Controlled Trials**

At least 13 RCTs of ICDs for primary prevention have been conducted. Five were in populations with ischemic cardiomyopathy with prior MI (usually ≥3 week’s post-MI):

- Multicenter Automatic Defibrillator Implantation Trial (MADIT);
- MADIT II;
- Coronary Artery Bypass Graft (CABG) Patch trial;

- Multicenter Unsustained Tachycardia Trial (MUSTT); and
- Sudden Cardiac Death in Heart Failure (SCD HeFT).

Three trials were conducted in patients implanted with ICD in the first few weeks following MI (recent MI):

- Defibrillator in Acute Myocardial Infarction Trial (DINAMIT);
- Immediate Risk Stratification Improves Survival (IRIS); and
- BEta-blocker STRategy plus ICD (BEST-ICD).

Six trials were in populations with NIDCM:

- Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION);
- Amiodarone Versus Implantable Cardioverter-Defibrillator (AMIOVIRT);
- Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE);
- SCD HeFT;
- Cardiomyopathy Trial (CAT); and
- Danish Study to Assess the Efficacy of ICDs in Patients with Non-Ischemic Systolic Heart Failure on Mortality (DANISH).

The trial characteristics and mortality results are shown in Table 3.

Most of the trials for both ischemic and nonischemic cardiomyopathy reported results consistent with a mortality benefit for ICD in patients with left ventricular systolic dysfunction or with heart failure and reduced ejection fraction although not all trials were powered for the mortality outcome and some findings were not statistical significant. However, the DINAMIT, IRIS, and BEST-ICD trials do not support a mortality benefit for ICD in the early weeks following MI and CABG-Patch showed no benefit in patients having recently undergone coronary revascularization. Another notable exception is the 2016 DANISH trial, which enrolled primarily outpatients with non-ischemic cardiomyopathy in stable condition who were almost all receiving  $\beta$ -blocker or ACE inhibitors with the majority also receiving mineralocorticoid-receptor antagonists. While overall mortality did not differ significantly between the ICD and medical therapy groups in DANISH, SCD was significantly reduced in the ICD group (4% vs. 8%; HR=0.50; 95% CI, 0.31 to 0.82).

**Table 3: Characteristics and Results of RCTs of Implantable Cardiac Defibrillators for Primary Prevention**

Trial	Participants	Treatment Groups		Mean Follow-up		Mortality Results
		Groups	N		Hazard Ratio	95% CI
<b>Ischemic cardiomyopathy with prior MI</b>						
MADIT (1996)	<ul style="list-style-type: none"> <li>• LVEF <math>\leq</math>35%</li> <li>• Asymptomatic non-SVT</li> <li>• MI <math>\geq</math>3 wk prior</li> <li>• Inducible VT</li> <li>• NYHA class I-III</li> </ul>	<ul style="list-style-type: none"> <li>• ICD</li> <li>• Standard therapy</li> </ul>	95 101	27 mo (trial stopped early by DSMB)	0.46	0.26-0.82
MADIT II (2002)	<ul style="list-style-type: none"> <li>• LVEF <math>\leq</math>30%</li> <li>• No history VT</li> <li>• MI <math>\geq</math>1 mo prior</li> <li>• NYHA class I-III</li> </ul>	<ul style="list-style-type: none"> <li>• ICD</li> <li>• Standard therapy</li> </ul>	742 490	20 mo (trial stopped early by DSMB)	0.69	0.51-0.93

CABG Patch (1997)	<ul style="list-style-type: none"> <li>Scheduled for CABG</li> <li>LVEF <math>\leq</math>35%</li> <li>No sustained VT or VF</li> <li>Age &gt; 80 y</li> <li>Signal-averaged ECG abnormalities</li> <li>82% had prior MI, time since MI not reported</li> </ul>	<ul style="list-style-type: none"> <li>ICD during CABG</li> <li>No ICD</li> </ul>	446 454	32 mo	1.07	0.81-1.42
MUSTT (1999)	<ul style="list-style-type: none"> <li>LVEF <math>\leq</math>40%</li> <li>Asymptomatic non-SVT</li> <li>Inducible VT</li> <li>MI <math>\geq</math>4 d prior (median, <math>\approx</math>3 y prior)</li> </ul>	<ul style="list-style-type: none"> <li>EPS-guided therapy (AAD w/wo ICD) (202 got ICD)</li> <li>Standard therapy</li> </ul>	351 353	39 mo	5-y outcomes <sup>b</sup> EPS guided vs. standard therapy <ul style="list-style-type: none"> <li>0.80 ICD vs. AAD alone</li> <li>0.42</li> </ul>	0.64-1.01 0.29-0.61
SCD HeFT (2005)	<ul style="list-style-type: none"> <li>LVEF <math>\leq</math>35%</li> <li>NYHA class I-III</li> <li>No asymptomatic SVT</li> <li>52% received ICM</li> <li>Treated with ACE inhibitors &amp; <math>\beta</math> blockers</li> </ul>	Ischemic Patients <ul style="list-style-type: none"> <li>ICD</li> <li>Amiodarone</li> <li>Placebo</li> </ul>	431 426 453	45 mo	ICD vs. Placebo Ischemic <ul style="list-style-type: none"> <li>0.79<sup>a</sup></li> </ul> Overall <ul style="list-style-type: none"> <li>0.77<sup>a</sup></li> </ul>	0.60-1.04 0.62-0.96
<b>Ischemic cardiomyopathy with recent MI</b>						
DINAMIT (2004)	<ul style="list-style-type: none"> <li>LVEF <math>\leq</math>35%</li> <li>NYHA class I-III</li> <li>No asymptomatic SVT</li> <li>MI in preceding 6-40 d (mean 18 d)</li> <li>No sustained VT or VF for &gt;48h after index MI</li> <li>Reduced HR variability or elevated resting HR</li> </ul>	<ul style="list-style-type: none"> <li>ICD</li> <li>Standard therapy</li> </ul>	332 342	30 mo	1.08	0.76-1.55
IRIS (2009)	<ul style="list-style-type: none"> <li>MI in preceding 5-31 d</li> <li>At least 1 of the following <ul style="list-style-type: none"> <li>LVEF <math>\leq</math>40% and resting HR <math>\geq</math>90 or non-SVT</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>ICD</li> <li>Standard therapy</li> </ul>	445 453	37 mo	1.04	0.81-1.35
BEST-ICD (2005)	<ul style="list-style-type: none"> <li>LVEF <math>\leq</math>35%</li> <li>NYHA class I-III</li> <li>No unsustained VT or sustained ventricular arrhythmias (except primary VF)</li> <li>MI in preceding 5-31 d</li> <li>At least one other risk factor</li> </ul>	<ul style="list-style-type: none"> <li>EPS-guided therapy (24 got ICD)</li> <li>Standard therapy</li> </ul>	49 59	540 d	1 year mortality <sup>d</sup> <ul style="list-style-type: none"> <li>EPS guided therapy 14%</li> <li>Conventional therapy 18%</li> </ul> 2 year mortality <sup>d</sup> <ul style="list-style-type: none"> <li>EPS guided therapy 20%</li> <li>Conventional therapy 29.5%</li> </ul>	
<b>Nonischemic cardiomyopathy</b>						
DEFINITE (2004)	<ul style="list-style-type: none"> <li>LVEF <math>\leq</math>35%</li> <li>NYHA class II-IV</li> </ul>	<ul style="list-style-type: none"> <li>ICD and medical therapy</li> <li>Medical therapy alone</li> </ul>	229 229	29 mo	0.65 (0.40 to 1.06)	

SCD HeFT (2005)	<ul style="list-style-type: none"> <li>LVEF<math>\leq</math>35%</li> <li>NYHA class II-III</li> <li>48% with non-ICM</li> <li>Treated with ACE inhibitor and <math>\beta</math> blocker</li> </ul>	Nonischemic patients <ul style="list-style-type: none"> <li>ICD</li> <li>Amiodarone</li> <li>Placebo</li> </ul>	398 419 394	45 mo	ICD vs. Placebo Nonischemic <ul style="list-style-type: none"> <li>0.73<sup>a</sup></li> </ul> Overall <ul style="list-style-type: none"> <li>0.77<sup>a</sup></li> </ul>	0.50-1.07 0.62-0.96
COMPANION (2004)	<ul style="list-style-type: none"> <li>LVEF<math>\leq</math>35%</li> <li>NYHA class III-IV</li> <li>DCM</li> </ul>	Nonischemic pts <ul style="list-style-type: none"> <li>CRT-ICD</li> <li>Medical therapy</li> <li>CRT</li> </ul>	270 127 285	16 mo	CRT-ICD vs. medical therapy Nonischemic <ul style="list-style-type: none"> <li>0.50</li> </ul> Overall <ul style="list-style-type: none"> <li>0.64</li> </ul>	0.29-0.88 0.48-0.86
AMIPVIRT (2003)	<ul style="list-style-type: none"> <li>LVEF<math>\leq</math>35%</li> <li>NYHA class I-III</li> <li>DCM</li> <li>Asymptomatic unsustained VT</li> </ul>	<ul style="list-style-type: none"> <li>ICD</li> <li>Amiodarone</li> </ul>	51 52	2 y	1-y survival <sup>d</sup> <ul style="list-style-type: none"> <li>ICD 96%</li> <li>Amiodarone 90%</li> </ul> 2 -y survival <sup>d</sup> <ul style="list-style-type: none"> <li>ICD 88%</li> <li>Amiodarone 87%</li> </ul>	
CAT (2002)	<ul style="list-style-type: none"> <li>LVEF<math>\leq</math>30%</li> <li>NYHA class II-III</li> <li>No symptomatic VT or VF or bradycardia</li> <li>Recent onset DCM</li> </ul>	<ul style="list-style-type: none"> <li>ICD</li> <li>Control</li> </ul>	50 54	23 mo (trials stopped early due to low event rates)	<ul style="list-style-type: none"> <li>ICD 4 deaths (8%)</li> <li>Control 2 deaths (3.7%)</li> </ul>	
DANISH (2016)	<ul style="list-style-type: none"> <li>LVEF<math>\leq</math>35%</li> <li>NYHA class II-IV</li> <li>58% received CRT</li> <li>Almost all patients on ACE inhibitors or <math>\beta</math> blockers; <math>\approx</math>60% treated with mineralocorticoid receptor antagonist</li> </ul>	<ul style="list-style-type: none"> <li>ICD and medical therapy</li> <li>Medical therapy</li> </ul>	556 560	5.6 y <sup>c</sup>	0.87	0.68-1.12

AAD: antiarrhythmic drugs; ACE: angiotensin-converting enzyme; CABG: coronary artery bypass grafting; CI: confidence interval; CRT: cardiac resynchronization therapy; CRT-ICD: ; DCM: dilated cardiomyopathy; DSMB: Data Safety Monitoring Board; ECG: electrocardiogram; EPS: electrophysiologic study; HR: heart rate; NYHA: New York Heart Association; ICD: implantable cardioverter defibrillator; ICM: ischemic cardiomyopathy; LVEF: left ventricular ejection fraction; MI: myocardial infarction; RBBB: right bundle-branch block; SUDS: sudden unexplained death syndrome; SVT: sustained ventricular tachycardia; VF: ventricular fibrillation; VT: ventricular tachycardia.

<sup>a</sup> 97.5% confidence interval.

<sup>b</sup> Relative risk.

<sup>c</sup> Median.

<sup>d</sup> HR not given, no significant differences.

## Systematic Reviews

Characteristics and results of systematic reviews of primary prevention ICD trials are described in Tables 4 and 5. Woods et al (2015) published an individual patient data network meta-analysis of primary prevention RCTs of implantable cardiac devices including studies of patients with heart failure and reduced ejection fraction and excluding studies of patients with recent MI or coronary revascularization.<sup>18</sup> The COMPANION, DEFINITE, MADIT, MADIT II, SCD HeFT, AMIOVIRT, and CAT trials were included representing 6134 patients for the direct ICD comparisons and 12,638 patients overall.

Subsequent systematic reviews and meta-analyses of ICD trials in nonischemic cardiomyopathy were published in 2017 incorporating the 2016 DANISH trial results and

updating previous meta-analysis.<sup>19-23</sup> Two of the 2017 reviews included CAT, AMIOVIRT, DEFINITE, SCD-HeFT, COMPANION, and DANISH trials; one review published in 2021 included the CAT, AMIOVIRT, DEFINITE, and DANISH trials; the other 2 reviews included all but the COMPANION trial. All 4 reviews concluded that there was a statistically significant overall reduction in mortality for ICD versus medical therapy, ranging from 20% to 23%, even with the inclusion of the null DANISH results.

Risk for death varies by age, sex, and clinical characteristics such as LVEF and time since revascularization and comorbid conditions such as diabetes and kidney disease. Meta-analyses have examined whether there is a beneficial effect on mortality of ICD in these subgroups. The Agency for Healthcare Research and Quality (AHRQ) sponsored a review of evidence for ICD across important clinical subgroups published in 2014.<sup>24</sup> The authors included 10 studies that provided subgroup analyses. Subgroup data were available from at least 4 studies for sex (<65 years vs. ≥65 years), age, and QRS interval (<120 ms vs. ≥ 120 ms) and were combined to calculate a relative odds ratio (ROR) using random-effects meta-analyses. There was no statistically significant difference in the mortality benefit by sex (ROR=0.95; 95% CI, 0.75 to 1.27), age (ROR=0.93; 95% CI, 0.73 to 1.20), or QRS interval (ROR=1.13; 95% CI, 0.82 to 1.54). Other comparisons of subgroups were not meta-analyzed because too few studies compared them; however, no consistent differences between subgroups were found across studies for diabetes. The Woods 2015 IPD network meta-analysis described previously also examined ICD versus medical therapy in various subgroups and similarly concluded that ICD reduced mortality in patients with heart failure and reduced ejection for QRS interval less than 120 ms, 120 to 149 ms, and 150 or higher, and age less than 60 and 60 and older and for men.<sup>18</sup> However, the effect on mortality in women was not statistically significant (HR=0.93; 95% CI, 0.73 to 1.18).

**Table 4. Characteristics of Systematic Reviews & Meta-Analysis of ICDs for Primary Prevention**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Woods (2015)	1990-2010	13	Patients with heart failure who received ICD	12,638 (17–2,521)	RCT	NR
Earley (2014)	1996-2010	14	Adults eligible to receive an ICD for primary prevention of SCD	NR	RCT, Nonrandomized comparative studies	NR

NR: not reported; ICD: implantable cardioverter defibrillator; RCT: randomized controlled trial; SCD: sudden cardiac death.

**Table 5. Results of Systematic Reviews & Meta-Analysis of ICDs for Primary Prevention**

Study	Mortality
Woods (2015)	<b>Estimated Effect of ICD on Mortality Compared with MT</b> 0.71 (CI 0.63–0.80)
Earley (2014)	<b>Mortality Benefit of Variables (ROR)</b>
Sex	0.95 (CI 0.75–1.27)
Age	0.93 (CI 0.73–1.20)
QRS interval	1.13 (CI 0.82–1.54)

MT: medical therapy; CI: 95% confidence interval; ROR: relative odds ratio; ICD: implantable cardioverter defibrillator.

## Registry Studies

Fontenla et al (2016) reported results from the Spanish UMBRELLA registry, a multicenter, observational, prospective nationwide registry of 1514 patients implanted with Medtronic ICDs equipped with remote monitoring enrolled between August 2012 and October 2013.<sup>25</sup> Mean age was 64 years; 82% of the patients were men; 65% received an ICD for primary prevention. Fifty-one percent of the patients had ischemic heart disease, 30% had nonischemic cardiomyopathy, 7% had HCM, 3% had Brugada syndrome (BrS), and 1.4% had long QT syndrome (LQTS). Mean follow-up was 26 months. The cumulative incidence of sustained ventricular arrhythmias was 15% (95% CI, 13% to 16%) at 1 year, 23% (95% CI, 21% to 25%) at 2 years, and 31% (95% CI, 28% to 34%) at 3 years. Thirteen percent of the episodes of sustained ventricular arrhythmias were self-terminated and did not require shocks. One hundred seventy-five (12%) patients had 482 appropriate shocks and 76 (5%) patients had 190 inappropriate shocks.

### **High-Risk Hypertrophic Cardiomyopathy (HCM)**

Schinkel et al (2012) reported results of a systematic review and meta-analysis of 27 observational studies including 16 cohorts and 2190 patients reporting outcomes after ICD therapy in HCM.<sup>26</sup> Most patients (83%) received an ICD for primary prevention of SCD. Mean age was 42, 38% of patients were women, and patients had a mean of 1.8 risk factors for SCD. With a mean follow-up of 3.7 years, 14% of patients had an appropriate ICD intervention with an annualized rate of 3.3%. Twenty percent of patients had an inappropriate ICD intervention, for an annualized rate of 4.8%. The annualized cardiac mortality rate was 0.6%, noncardiac mortality rate was 0.4%, and heart transplantation rate was 0.5%.

In 2015, Magnusson et al reported outcomes for 321 patients with HCM treated with an ICD enrolled in a Swedish registry.<sup>27</sup> Over a mean follow-up of 5.4 years, appropriate ICD discharges in response to VT or fibrillation (VF) occurred in 77 (24%) patients, corresponding to an annual rate of appropriate discharges of 5.3%. At least 1 inappropriate shock occurred in 46 (14.3%) patients, corresponding to an annualized event rate of 3.0%. Ninety-two (28.7%) patients required at least 1 surgical intervention for an ICD-related complication, with a total of 150 ICD-related reinterventions. Most reinterventions (n=105 [70%]) were related to lead dysfunction.

### **Inherited Cardiac Ion Channelopathy**

ICDs have been used for primary and secondary prevention in patients with a number of hereditary disorders, also called cardiac ion channelopathies, which predispose to ventricular arrhythmias and SCD, including LQTS, BrS, short QT syndrome (SQTS), and catecholaminergic polymorphic ventricular tachycardia (CPVT). Some of these conditions are extremely rare, but use of ICDs has been described in small cohorts of patients with LQTS, BrS, and CPVT.

### **Long QT Syndrome**

In 2010, Horner et al reported on outcomes for 51 patients with genetically confirmed LQTS treated with an ICD from 2000 to 2010 that were included in a single-center retrospective analysis of 459 patients with genetically confirmed LQTS.<sup>28</sup> Of patients treated with ICDs, 43 (84%) received the device as primary prevention. Twelve patients (24%) received appropriate VF or torsades de pointes-terminated ICD shocks. Factors associated with appropriate shocks included secondary prevention indications (p=0.008), QT corrected (QTc) duration greater than 500 ms (p<0.001), non-LQT3 genotype (p=0.02), documented syncope (p=0.05), documented torsades de pointes (p=0.003), and a *negative* sudden family death history

( $p < 0.001$ ). Inappropriate shocks were delivered in 15 patients (29%). Patients with the LQT3 genotype had only received inappropriate shocks.

### **Brugada Syndrome**

Hernandez-Ojeda et al (2017) reported on results from a single-center registry of 104 patients with Brugada syndrome (BrS) who were treated with ICDs.<sup>29</sup> Ten (9.6%) patients received an ICD for secondary prevention and in 94 (90.4%) patients received an ICD for primary prevention. During the average 9.3 year follow-up, 21 (20.2%) patients received a total of 81 appropriate shocks. In multivariate analysis, type 1 electrocardiogram with syncope and secondary prevention indication were significant predictors of appropriate therapy. Nine (8.7%) patients received 37 inappropriate shocks. Twenty-one (20.2%) patients had other ICD-related complications.

Conte et al (2015) described outcomes for a cohort of 176 patients with spontaneous or drug-induced Brugada type 1 electrocardiographic (ECG) findings received an ICD at a single institution and were followed for at least 6 months.<sup>30</sup> Before ICD implantation, 14.2% of subjects had a history of aborted SCD due to sustained spontaneous ventricular arrhythmias, 59.7% had at least 1 episode of syncope, and 25.1% were asymptomatic. Over a mean follow-up of 83.8 months, 30 (17%) patients had spontaneous sustained ventricular arrhythmias detected. Sustained ventricular arrhythmias were terminated by ICD shocks or antitachycardia pacing in 28 (15.9%) patients and 2 (1.1%) patients, respectively. However, 33 (18.7%) patients experienced inappropriate shocks.

Dores et al (2015) reported results of a Portuguese registry that included 55 patients with Brugada syndrome, 36 of whom were treated with ICDs for either primary or secondary prevention.<sup>31</sup> Before ICD implantation, 52.8% of subjects were asymptomatic, 30.6% had a history of syncope with suspected arrhythmic cause, and 16.7% had a history of aborted SCD. Over a mean follow-up of 74 months, 7 patients experienced appropriate shocks, corresponding to an incidence of 19.4% and an annual event rate of 2.8%. In multivariable analysis, predictors of appropriate shocks were a history of aborted SCD (HR=7.87; 95% CI, 1.27 to 49.6;  $p=0.027$ ) and nonsustained VT during follow-up (HR=6.73; 95% CI, 1.27 to 35.7;  $p=0.025$ ).

### **Catecholaminergic Polymorphic Ventricular Tachycardia**

Roses-Noguer et al (2014) reported results of a small retrospective study of 13 patients with CPVT who received an ICD.<sup>32</sup> The indication for ICD therapy was syncope despite maximal  $\beta$ -blocker therapy in 6 (46%) patients and aborted SCD in 7 (54%) patients. Over a median follow-up of 4.0 years, 10 (77%) patients received a median 4 shocks. For 96 shocks, 87 ECGs were available for review; of those, 63 (72%) were appropriate and 24 (28%) were inappropriate. Among appropriate shocks, 20 (32%) were effective in restoring sinus rhythm.

### **Cardiac Sarcoid**

Sarcoidosis is a systemic granulomatous disease of unknown etiology, with a worldwide prevalence of about 4.7–64 in 100,000.<sup>33</sup> The annual incidence of sarcoidosis in the United States has been estimated at 10.9 per 100,000 in white individuals and 35.5 per 100,000 in black individuals. Cardiac involvement occurs in about 5% of systemic sarcoidosis cases. Steroid therapy is recommended as first-line treatment based on small cohort studies showing benefit, although there is conflicting evidence about its efficacy on long-term disease outcomes.<sup>34</sup>

Mantini et al (2012) published a review on the diagnosis and management of cardiac sarcoid, including a treatment algorithm.<sup>35</sup> Limited evidence from small cohort studies suggested that an ICD could prevent dangerous arrhythmias or SCD even in patients with a relatively preserved LVEF. Evidence from case series also suggested that programmed electrical stimulation could identify cardiac sarcoid patients with electrical instability and help to determine who should get ICD.

## **Section Summary: Transvenous Implantable Cardioverter Defibrillators for Primary Prevention in Adults**

### **Ischemic Cardiomyopathy and NIDCM**

A large body of RCTs has addressed the effectiveness of T-ICD implantation for primary prevention in patients at high risk of SCD due to ischemic cardiomyopathy and NIDCM. Evidence from several RCTs has demonstrated improvements in outcomes with ICD treatment for patients with symptomatic heart failure due to ischemic or NICM with LVEF of 35% or less. The notable exceptions are that data from several RCTs, including the BEST-ICD, DINAMIT and IRIS trials and subanalyses from earlier RCTs, show that outcomes with ICD therapy do not appear to improve for patients treated with an ICD within 40 days of recent MI and the CABG Patch trial did not find a benefit for patients undergoing coronary revascularization.

### **Hypertrophic Cardiomyopathy**

Less evidence is available for use of ICDs for primary prevention in patients with HCM. In a meta-analysis of cohort studies, the annual rates of appropriate T-ICD discharge was 3.3% and the mortality rate was 1%. Given the long-term high risk of patients with HCM for SCD risk, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence for the use of SCDs in patients with HCM.

### **Inherited Cardiac Ion Channelopathy**

The evidence related to the use of ICDs in patients with inherited cardiac ion channelopathy includes primarily single-center cohort studies or registries of patients with LQTS, BrS, and CPVT that report on appropriate shock rates. Patient populations typically include a mix of those requiring ICD implantation for primary or secondary prevention. The limited available data for ICDs for LQTS and CPVT have reported high rates of appropriate shocks. For BrS, more data are available and have suggested that rates appropriate shocks are similarly high. Studies comparing outcomes between patients treated and untreated with ICDs are not available. However, given the relatively small patient populations and the high risk of cardiac arrhythmias, clinical trials are unlikely. Given the long-term high risk of patients with inherited cardiac ion channelopathy for SCD risk, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence for the use of SCDs in patients with inherited cardiac ion channelopathy.

### **Cardiac Sarcoid**

The evidence related to the use of ICDs in patients with cardiac sarcoid includes small cohort studies of patients with cardiac sarcoid treated with ICDs who received appropriate shocks. Studies comparing outcomes between patients treated and untreated with ICDs are not available. However, given the relatively small number of patients with cardiac sarcoid (5% of those with systemic sarcoidosis), clinical trials are unlikely. Given the long-term high-risk of



SCD in patients with cardiac sarcoid, with the assumption that appropriate shocks are life-saving, these studies are considered adequate evidence to support the use of T-ICDs in patients with cardiac sarcoid who have not responded to optimal medical therapy.

### **Primary Prevention in Pediatric Populations**

There is limited direct evidence on the efficacy of ICDs in the pediatric population. Most published studies have retrospectively analyzed small case series that included mixed populations with mixed indications for device placement. Some representative series are reviewed next.

The largest published series, by Berul et al (2008), combined pediatric patients and patients with congenital heart disease from 4 clinical centers.<sup>36</sup> Median age was 16 years, although some adults included were as old as 54 years. A total of 443 patients were included. The most common diagnoses were tetralogy of Fallot and HCM. ICD placement was performed for primary prevention in 52% of patients and secondary prevention in 48%. Over a 2-year follow-up, appropriate shocks occurred in 26% of patients and inappropriate shocks occurred in 21%.

Silka et al (1993) compiled a database of 125 pediatric patients treated with an ICD through a query of the manufacturers of commercially available devices.<sup>37</sup> Indications for ICD placement were survivors of cardiac arrest (95 [76%] patients), drug-refractory VT (13 [10%] patients), and syncope with heart disease and inducible VT (13 [10%] patients). During a mean follow-up of 31 months, 73 (59%) patients received at least 1 appropriate shock and 25 (20%) received at least 1 inappropriate shock. Actutimes rates of SCD-free survival were 97% at 1 year, 95% at 2 years, and 90% at 5 years.

Alexander et al (2004) reported on 90 ICD procedures in 76 young patients (mean age, 16 years; range, 1-30 years).<sup>38</sup> Indications for placement were 27 (36%) patients with cardiac arrest or sustained VT, 40 (53%) with syncope, 17 (22%) with palpitations, 40 (53%) with spontaneous ventricular arrhythmias, and 36 (47%) with inducible VT. Numerous patients had more than one indication for ICD in this study. Over a median follow-up of 2 years, 28% of patients received an appropriate shock and 25% received an inappropriate shock.

Lewandowski et al (2010) reported on long-term follow-up for 63 patients, between the ages 6 and 21 years, who were treated with an ICD device.<sup>37</sup> At 10-year follow-up, 13 (21%) patients had surgical infections. Fourteen (22%) patients experienced at least 1 appropriate shock and 17 (27%) had at least 1 inappropriate shock. Serious psychological sequelae developed in 27 (43%) patients.

### **Section Summary: Primary Prevention in Pediatric Populations**

The available evidence for the use of ICDs in pediatric patients is limited and consists primarily of small case series that include mixed populations with mixed indications for device placement. Overall, these studies have reported both relatively high rates of appropriate and inappropriate shocks. Pediatric patients may be eligible for ICD placement if they have inherited cardiac ion channelopathy (see Inherited Cardiac Ion Channelopathy section).

## **Transvenous Implantable Cardioverter Defibrillators for Secondary Prevention**

### **Clinical Context and Therapy Purpose**

The purpose of T-ICD placement is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with life-threatening ventricular tachyarrhythmia or fibrillation or who have been resuscitated from sudden cardiac arrest.

The following **PICOs** was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals with life-threatening ventricular tachyarrhythmia or fibrillation or who have been resuscitated from sudden cardiac arrest.

### **Interventions**

The therapy being considered is T-ICD placement. An ICD is a device designed to monitor a patient's heart rate, recognize ventricular fibrillation or ventricular tachycardia, and deliver an electric shock to terminate these arrhythmias to reduce the risk of sudden death.

### **Comparators**

Comparators of interest include medical management without ICD placement.

### **Outcomes**

The general outcomes of interest are overall survival (OS), morbid events, quality of life, treatment-related mortality, and treatment-related morbidity.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Secondary Prevention in Adults**

At least 5 trials of ICD in combination with medical therapy compared with medical therapy alone have been conducted in the secondary prevention setting: Antiarrhythmics Versus Implantable Defibrillators (AVID) trial<sup>40</sup> (N=1016), Cardiac Arrest Survival in Hamburg (CASH) trial<sup>41</sup> (N=288), Canadian Implantable Defibrillator Study (CIDS)<sup>42</sup> (N=659), Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT)<sup>43</sup> trial (N=66; pilot, n=20; main study, n=46), and Wever et al (1995)<sup>44</sup> (N=60). The trials are shown in Table 6. Mean length of follow-up varied from 18 to 57 months across trials. Lee et al (2003) combined AVID, CASH, CIDS, and Wever et al in a meta-analysis of secondary prevention trials.<sup>45</sup> The mortality analysis included 2023 participants and 518 events. In combined estimates, ICD group had a significant reduction in both mortality (HR=0.75; 95% CI, 0.64 to 0.87) and SCD (HR=0.50; 95% CI, 0.34 to 0.62) compared with those receiving medical therapy. To support NICE guidance on use of ICDs, a meta-analysis of AVID, CASH, CIDS, and the pilot DEBUT participants were combined in a meta-analysis.<sup>46</sup> The results were similar, indicating a reduction in mortality for ICDs compared with medical therapy (RR=0.75; 95% CI, 0.61 to

0.93). Two other meta-analyses including AVID, CIDS, and CASH reached similar conclusions.<sup>47,48</sup>

**Table 6: RCTs of ICDs for Secondary Prevention**

Trial	Participants	Treatment Groups		Mortality Results	
		Groups	N	RR	95% CI
AVID (1997)	Patients resuscitated from near-fatal VT/VF, SVT w/syncope, or SVT with LVEF $\leq$ 0.40 and symptoms	<ul style="list-style-type: none"> <li>ICD</li> <li>AAD</li> </ul>	507 509	0.66	0.51 to 0.85
CASH (2000)	Patients resuscitated from cardiac arrest due to sustained ventricular arrhythmia	<ul style="list-style-type: none"> <li>ICD</li> <li>Amiodarone</li> <li>Metoprolol</li> </ul>	99 92 97	0.82	0.60 to 1.11
CIDS (2000)	Patients with VF, out of hosp cardiac arrest requiring defibrillation, VT w/syncope, VT w/rate $\geq$ 150/min causing presyncope or angina in patient with LVEF $\leq$ 0.35, or syncope w/inducible VT	<ul style="list-style-type: none"> <li>ICD</li> <li>Amiodarone</li> </ul>	328 331	0.85	0.67 to 1.10
Wever et al (1995)	Patients with previous MI and resuscitated cardiac arrest due to VT or VT and inducible VT	<ul style="list-style-type: none"> <li>ICD</li> <li>AAD</li> </ul>	29 31	0.39	0.14 to 1.08
DEBUT (2003)	Patients were either SUDS survivors or probable SUDS with ECG abnormalities, RBBB-like pattern w/ST elevation in the right precordial leads and inducible VT/VF	Pilot <ul style="list-style-type: none"> <li>ICD</li> <li><math>\beta</math> blocker</li> </ul> Main Trial <ul style="list-style-type: none"> <li>ICD</li> <li><math>\beta</math> blocker</li> </ul>	10 10 37 29	<ul style="list-style-type: none"> <li>RR not calculable (DSMB stopped trial early due to efficacy of ICD)</li> <li>7 deaths in <math>\beta</math> blocker therapy vs. 0 in ICDs</li> </ul>	

AAD: antiarrhythmic drugs; CI: confidence interval; DSMB: data safety monitoring board; ICD: implantable cardioverter defibrillator; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; RBBB: right bundle-branch block; RR: relative risk; SUDS: sudden unexplained death syndrome; SVT: sustained ventricular tachycardia; VF: ventricular fibrillation; VT: ventricular tachycardia.

An analysis by Chan and Hayward (2005) using the National Veterans Administration database confirmed that this mortality benefit was generalizable to the clinical setting.<sup>49</sup> A cohort of 6996 patients in the National Veterans Affairs database from Austin, Texas, from 1995 to 1999 with new-onset ventricular arrhythmia and preexisting ischemic heart disease and congestive heart failure were included. Of those, 1442 patients had received an ICD. Mortality was determined through the National Death Index at 3 years from the hospital discharge date. The cohort was stratified by quintiles of a multivariable propensity score created using many demographic and clinical confounders. The propensity score adjusted mortality reduction for ICD compared to no ICD was a relative risk of 0.72 (95% CI, 0.69 to 0.79) for all-cause mortality and a relative risk of 0.70 (95% CI, 0.63 to 0.78) for cardiovascular mortality.

### Section Summary: Secondary Prevention in Adults

Systematic reviews of RCTs in patients who have experienced symptomatic life-threatening sustained VT/VF or have been successfully resuscitated from sudden cardiac arrest show a 25% reduction in mortality for ICD compared to medical therapy. Analysis of data from a large

administrative database confirms that this mortality benefit is generalizable to the clinical setting.

### **Secondary Prevention in Pediatric Populations**

There is limited direct evidence on the efficacy of ICDs in the pediatric population. Most published studies have retrospectively analyzed small case series that included mixed populations with mixed indications for device placement. Some representative series were reviewed above (see Primary Prevention in Pediatric Populations section).

### **Section Summary: Secondary Prevention in Pediatric Populations**

The available evidence for the use of ICDs in pediatric patients is limited and consists primarily of small case series that include mixed populations with mixed indications for device placement. Overall, these studies have reported both relatively high rates of appropriate and inappropriate shocks. Pediatric patients may be eligible for ICD placement if they have inherited cardiac ion channelopathy (see Inherited Cardiac Ion Channelopathy section).

## **ADVERSE EVENTS ASSOCIATED WITH T-ICDS**

### **Systematic Reviews: Mixed Adverse Events**

Characteristics and results of systematic reviews of adverse events associated with transvenous ICDs are described in Tables 7 and 8. Persson et al (2014) conducted a systematic review of adverse events following ICD placement.<sup>50</sup> In-hospital serious adverse event rates ranged from 1.2% to 1.4%, most frequently pneumothorax (0.4% to 0.5%) and cardiac arrest (0.3%).

In another systematic review and meta-analysis of AEs following ICD implantation, Ezzat et al (2015) compared rates of AEs reported in clinical trials of ICDs with those reported in the U.S. National Cardiovascular Data Registry.<sup>51</sup> Complication rates in the RCTs were higher than those in the U.S. registry, which reports only in-hospital complications (9.1% in the RCTs vs. 3.08% in the U.S. registry,  $p < 0.01$ ). The overall complication rate was similar to that reported by Kirkfelt et al (2014), in a population-based cohort study including all Danish patients who underwent a cardiac implantable electronic device procedure from 2010 to 2011 (562 [9.5%] 5918 patients with at least 1 complication).<sup>52</sup>

In 2011, van Rees et al (2011) reported results of a systematic review of implantation-related complications in RCTs of ICDs and cardiac resynchronization therapy (CRT) devices.<sup>53</sup> The review included 18 trials and 3 subgroup analyses. Twelve trials assessed ICDs, 4 of which used both thoracotomy and nonthoracotomy ICDs ( $n=951$ ) and 8 of which used nonthoracotomy ICDs ( $n=3828$ ). For nonthoracotomy ICD implantations, the rate of in-hospital and 30-day mortality was 0.2% and 0.6%, respectively, and pneumothorax was reported in 0.9% of cases. For thoracotomy ICD implantations, the average in-hospital mortality rate was 2.7%. For nonthoracotomy ICD implantations, the overall lead-dislodgement rate was 1.8%.

In 2016, Olde Nordkamp et al reported on a systematic review and meta-analysis of studies reporting on ICD complications in individuals with inherited arrhythmia syndromes.<sup>54</sup> Reviewers included 63 cohort studies with a total of 4916 patients (710 [10%] with

arrhythmogenic right VT; 1037 [21%] with BrS; 28 [0.6%] with CPVT; 2466 [50%] with HCM; 162 [3.3%] with lamin A/C gene variants; 462 [9.4%] with LQTS; 51 [1.0%] with SQTS).

**Table 7. Systematic Reviews & Meta-Analysis Characteristics for Adverse Events Associated with T-ICDs**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Persson (2014)	2005-2012	53 trials; 35 cohorts	Patients receiving ICD placement	NR	Cohort Studies	NR
Ezzat (2015)	2001-2011	18	Patients receiving ICD placement	6796 (16–1530)	RCT	NR
Olde Nordkamp (2016)	1997-2014	63	Patients with inherited arrhythmia syndromes receiving ICD placement	4916 (NR)	Cohort	NR

ICD: implantable cardioverter defibrillator; NR: not reported; RCT: randomized controlled trials; T-ICD: transvenous implantable cardioverter defibrillator.

**Table 8. Systematic Reviews & Meta-Analysis Results for Adverse Events Associated with T-ICDs**

Study	Rate of Adverse Events	Rates of Specific Complications
Persson (2014)		
Range	1.2%–1.4% <sup>1</sup>	Device-related: <0.1%–6.4% Lead-related: <0.1%–3.9% Infection: 0.2%–3.7% Inappropriate shock: 3%–21%
Ezzat (2015)	9.1 (CI 6.4%–12.6%)	Access-related: 2.1% (CI 1.3%–3.3%) Lead-related: 5.8% (CI 3.3%–9.8%) Generator-related: 2.7% (CI 1.3%–5.7%) Infection: 1.5% (CI 0.8%–2.6%)
Olde Nordkamp (2016)	22% (4.4% per year; 3.6%–5.2%; p<0.001)	Lead malfunction: 10.3% Infection: 3.0% (0.53% per year) Inappropriate shock: 20% (4.7% per year; CI 4.2%–5.3%; p<0.001)

CI: 95% confidence interval; T-ICD: transvenous implantable cardioverter defibrillator.

<sup>1</sup>Only serious adverse events, which included cardiac arrest, cardiac perforation, cardiac valve injury, coronary venous dissection, hemothorax, pneumothorax, deep phlebitis, transient ischemic attack, stroke, myocardial infarction, pericardial tamponade, arteriovenous fistula, and, in one study, lead dislodgement.

## Systematic Reviews: Specific Complications

### Lead Failure

The failure of ICD leads in several specific ICD devices has led the U.S. FDA to require St. Jude Medical to conduct three-year postmarket surveillance studies to address concerns related to premature insulation failure and to address important questions related to follow-up of affected patients.<sup>55</sup> A 2010 report found that 57 deaths and 48 serious cardiovascular injuries associated with device-assisted ICD or pacemaker lead extraction were reported to the FDA's Manufacturers and User Defined Experience (MAUDE) database.<sup>56</sup>

In 2015, Providencia et al reported on a meta-analysis of observational studies evaluating lead performance.<sup>57</sup> Seventeen studies with a total of 49,871 leads (5538 Durata, 10,605 Endotak Reliance, 16119 Sprint Quattro, 11,709 Sprint Fidelis, and 5900 Riata). Overall, the incidence of lead failure was 0.93 per 100 lead-years (95% CI 0.88 to 0.98). In analysis of

studies restricted to head-to-head comparisons of leads, there was no significant difference in the lead failure rate among non-recalled leads (Endotak Reliance, Durata, and Sprint Quattro).

Birnie et al (2012) reported clinical predictors of failure for 3169 Sprint Fidelis leads implanted from 2003 to 2007 at 11 of 23 centers participating in the Canadian Heart Rhythm Society Device Committee.<sup>58</sup> A total of 251 lead failures occurred, corresponding to a lead failure rate at 5 years of 16.8%. Factors associated with higher rates of failure included female sex (HR=1.51; 95% CI, 1.14 to 2.04; p=0.005), axillary vein access (HR=1.94; 95% CI, 1.23 to 3.04), and subclavian vein access (HR=1.63; 95% CI, 1.08 to 2.46). In a previous study from 3 centers reporting on predictors of Fidelis lead failures, compared with Quattro lead failures, Hauser et al reported a failure rate for the Fidelis lead of 2.81% per year (vs. 0.42%/y for Quattro leads, p<0.001).<sup>57</sup>

In a large prospective multicenter study, Poole et al (2010) reported complications rates associated with generator replacements and/or upgrade procedures of pacemaker or ICD devices, which included 1031 patients without a planned transvenous lead replacement (cohort 1) and 713 with a planned transvenous lead replacement (cohort 2).<sup>60</sup> A total of 9.8% and 21.9% of cohort 1 and 19.2% and 25.7% of cohort 2 had a single-chamber ICD and a dual-chamber ICD, respectively, at baseline. The overall periprocedural complication rates for those with a planned transvenous lead replacement were cardiac perforation in 0.7%, pneumothorax or hemothorax in 0.8%, cardiac arrest in 0.3%, and, most commonly, need to reoperate because of lead dislodgement or malfunction in 7.9%. Although rates were not specifically reported for ICD replacements, complication rates were higher for ICDs and CRT devices than pacemakers.

Ricci et al (2012) evaluated the incidence of lead failure in a cohort study of 414 patients implanted with an ICD with Sprint-Fidelis leads.<sup>61</sup> Patients were followed for a median of 35 months. Lead failures occurred in 9.7% (40/414) of patients, for an annual rate of 3.2% per patient-year. Most of the lead failures (87.5%) were due to lead fracture. The median time until recognition of lead failure, or until an adverse event, was 2.2 days. A total of 22 patients (5.3%) received an inappropriate shock due to lead failure.

Cheng et al (2010) examined the rate of lead dislodgements in patients enrolled in a national cardiovascular registry.<sup>62</sup> Of 226,764 patients treated with an ICD between April 2006 and September 2008, lead dislodgement occurred in 2,628 (1.2%). Factors associated with lead dislodgement were NYHA Class IV heart failure, atrial fibrillation/flutter, a combined ICD-CRT device, and having the procedure performed by a non-electrophysiologist. Lead dislodgement was associated with an increased risk for other cardiac adverse events and death.

In another single-center study, Faulknier et al (2010) reported on the time-dependent hazard of failure of the Sprint Fidelis leads for 426 leads implanted at a single center.<sup>63</sup> Over an average follow-up of 2.3 years, 38 (8.92%) leads failed. There was a 3-year survival of 90.8% (95% CI, 87.4% to 94.3%), with a hazard of fracture increasing exponentially over time by a power of 2.13 (95% CI, 1.98 to 2.27; p<0.001).

### **Infection Rates**

Several publications have reported on infection rates in patients receiving an ICD. Smit and Schonheyder published a retrospective, descriptive analysis of the types and distribution of infections associated with ICDs over a 10-year period in Denmark.<sup>64</sup> Of 91 total infections

identified, 39 (42.8%) were localized pocket infections, 26 (28.6%) were endocarditis, 17 (18.7%) were ICD-associated bacteremic infections, and 9 (9.9%) were acute postsurgical infections. Nery et al (2010) reported the rate of ICD-associated infections among consecutive patients treated with an ICD at a tertiary referral center.<sup>65</sup> There were a total of 24 infections among 2417 patients for a rate of 1.0%. Twenty-two of 24 patients with infections (91.7%) required device replacement. Factors associated with infection were device replacement (vs. de novo implantation) and use of a complex device (e.g., combined ICD-CRT or dual/triple chamber devices). Sohail et al (2011) performed a case-control study evaluating the risk factors for infection in 68 patients with an ICD infection and 136 matched controls.<sup>66</sup> On multivariate analysis, the presence of epicardial leads (odds ratio [OR], 9.7;  $p=0.03$ ) and postoperative complications at the insertion site (OR=27.2,  $p<0.001$ ) were significant risk factors for early infection. For late-onset infections, prolonged hospitalization for >3 days (OR=33.1,  $p<0.001$  for 2 days vs. 1 day) and chronic obstructive pulmonary disease (OR=9.8,  $p=0.02$ ) were significant risk factors.

Borleffs et al reported on complications after ICD replacement for pocket-related complications, including infection or hematoma, in a single-center study.<sup>67</sup> Of a total of 3161 ICDs included, 145 surgical reinterventions were required in 122 ICDs in 114 patients. Ninety-five (66%) reinterventions were due to infection and the remaining 50 (34%) were due to other causes. Compared with first-implanted ICDs, the occurrence of surgical reintervention in replacements was 2.5 (95% CI, 1.6 to 3.7) times higher for infectious and 1.7 (95% CI, 0.9 to 3.0) for noninfectious causes.

### **Inappropriate Shocks**

Inappropriate shocks may occur with ICDs due to inappropriate sensing or sensing of atrial arrhythmias with rapid ventricular conduction; they may lead to reduced quality of life and risk of ventricular arrhythmias. In the MADIT II study, described above, 1 or more inappropriate shocks occurred in 11.5% of ICD subjects and were associated with a greater likelihood of mortality (HR=2.29; 95% CI, 1.11 to 4.71;  $p=0.02$ ).<sup>68</sup>

Ten et al (2014) conducted a systematic review to identify outcomes and adverse effects associated with ICDs that have built-in therapy reduction programming.<sup>69</sup> Six randomized trials and 2 nonrandomized cohort studies were included, including 7,687 patients (3,598 with conventional ICDs and 4,089 therapy reduction programming). A total of 267 patients received inappropriate ICD shocks (4.9%); 99 (3.4%) in the therapy reduction and 168 (6.9%) in the conventional programming group (relative risk 50%; 95% CI 37% to 61%;  $P<0.001$ ). Therapy reduction programming was associated with a significantly lower risk of death compared with conventional programming (relative risk 30%; 95% CI 16% to 41%;  $P<0.001$ .)

Sterns et al (2016) reported results of an RCT comparing a strategy using a prolonged ventricular fibrillation (VF) detection time to reduce inappropriate shocks with a standard strategy among secondary prevention patients.<sup>70</sup> The present study is a prespecified subgroup analysis of the PainFree SST trial, a trial comparing standard and prolonged detection in patients receiving an ICD for secondary prevention. Patients who were treated for secondary prevention indications were randomized to a prolonged VF detection period ("Number of Intervals to Detect" VF 30/40;  $n=352$ ) or a standard detection period ("Number of Intervals to Detect" VF 18/24;  $n=353$ ). At 1 year, arrhythmic syncope-free rates were 96.9% in the 30/40 (intervention) group and 97.7% in the 18/24 (control) group (rate difference -1.1%,

90% lower confidence limit of -3.5%, above the prespecified noninferiority margin of -5%; noninferiority P=0.0034).

Auricchio et al (2015) assessed data from the PainFree SST trial, specifically newer ICD programming strategies for reducing inappropriate shocks.<sup>71</sup> A total of 2790 patients with an indication for ICD placement were given a device programmed with a SmartShock Technology designed to differentiate between ventricular arrhythmias and other rhythms. The inappropriate shock incidence for dual-/triple-chamber ICDs was 1.5% at 1 year (95% CI, 1.0% to 2.1%), 2.8% at 2 years (95% CI, 2.1% to 3.8%), and 3.9% at 3 years (95% CI, 2.8% to 5.4%).

### **Other Complications**

Lee et al (2010) evaluated the rate of early complications among patients enrolled in a prospective, multi-center population-based registry of all newly implanted ICDs in Ontario, Canada from February 2007 through May 2009.<sup>72</sup> Of 3,340 patients receiving an ICD, major complications (lead dislodgement requiring intervention, myocardial perforation, tamponade, pneumothorax, infection, skin erosion, hematoma requiring intervention) within 45 days of implantation occurred in 4.1% of new implants. Major complications were more common in women, in patients who received a combined ICD-CRT (cardiac resynchronization therapy) device, and in patients with a left ventricular end-systolic size of larger than 45 mm. Direct implant-related complications were associated with a major increase in early death (HR: 24.9, p<0.01).

Furniss et al prospectively evaluated changes in high-sensitivity troponin T (hs-TnT) level and ECG that occur during ICD implantation alone, ICD implantation with testing, and ICD testing alone.<sup>73</sup> The 13 subjects undergoing ICD implantation alone had a median increase in hs-TnT of 95% (p=0.005) while the 13 undergoing implantation and testing had a median increase of 161% (p=0.005). Those undergoing testing alone demonstrated no significant change in hs-TnT levels.

## **SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS in Individuals with a Contraindication to a Transvenous Implantable Cardioverter Defibrillator**

### **Clinical Context and Therapy Purpose**

The purpose of subcutaneous implantable cardioverter defibrillators (S-ICD) placement is to provide a treatment option that is an alternative to or an improvement on existing therapies such as medical management without ICD placement, in patients who have an indication for cardioversion but have a contraindication to T-ICD.

The following **PICOs** were used to select literature to inform this review.

### **Populations**

The relevant population of interest are individuals who need an ICD and have a contraindication to T-ICD.

There are no defined guidelines for the selection of S-ICD versus T-ICD. Currently, S-ICDs are generally considered in the following situations:

- Individuals at high risk of infection, inadequate venous access, and any patient without a pacing indication



- Younger Individuals due to the expected longevity of the implanted leads and a desire to avoid chronic transvenous leads (e.g., patients with hypertrophic cardiomyopathy, congenital cardiomyopathies, or inherited channelopathies)
- Individuals at high risk for bacteremia, such as patients on hemodialysis or with chronic indwelling endovascular catheters.
- Individuals with challenging vascular access or prior complications with T-ICDs

## Interventions

The therapy being considered is S-ICD.

An ICD is a device designed to monitor a patient’s heart rate, recognize ventricular fibrillation or ventricular tachycardia, and deliver an electric shock to terminate these arrhythmias to reduce the risk of sudden death. A subcutaneous ICD (S-ICD, which lacks transvenous leads, is intended to reduce lead-related complications. The S-ICD is intended for patients who have standard indications for an ICD, but who do not require pacing for bradycardia or antitachycardia overdrive pacing for VT. The S-ICD is proposed to benefit patients with limited vascular access (including patients undergoing renal dialysis or children) or those who have had complications requiring T-ICDs explantation.

## Comparators

Comparators of interest include medical management without ICD placement or T-ICD placement.

## Outcomes

The general outcomes of interest are OS, morbid events, QOL, treatment-related mortality, and treatment-related morbidity. Table 9 describes outcomes of interest related to quality of life and treatment-related morbidity for individuals who need an ICD and have a contraindication to a T-ICD.

**Table 9. Outcomes of Interest for Individuals Who Need an Implantable Cardioverter Defibrillator and Have a Contraindication to Transvenous ICD**

Outcomes	Details	Timing
Quality of life	Can be assessed patient reported data such as surveys and questionnaires	1 week to 5 years
Treatment-related morbidity	Can be assessed rates of adverse events, including inappropriate shock, lead failure, infection, and other complications	1 week to 5 years

## Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## Review of Evidence

## Randomized Trials

Healey et al (2022) published 2.5 year interim results of the randomized, multicenter Avoid Transvenous Leads in Appropriate Subjects (ATLAS S-ICD) trial.<sup>74</sup> This trial included 544 individuals (141 female) with a primary or secondary prevention indication for an ICD who were younger than 60 years, had a cardiogenetic phenotype, or had prespecified risk factors for lead complications. Of those, 503 were randomized to S-ICD (n=251) or T-ICD (n=252). Mean age of included patients was 49 years. The primary outcome focused on perioperative complications that are lead-related. Within 6 months of implantation, perioperative, lead-related complications occurred in 1 patient (0.4%) with an S-ICD and in 12 patients (4.8%) with T-ICD (risk difference, -4.4%; 95% CI, -6.9 to -1.9; p=.001). Overall, complications between groups were similar at 6 months, including device-related infection requiring surgery (S-ICD, 11 patients vs T-ICD, 14 patients; risk difference, -1.2; 95% CI, -2.4 to 0.1). More patients in the S-ICD group experienced ICD site pain on the day of implant (p<.001) and 1 month later (p=.035) compared to T-ICD patients. There were no differences in pain scores at 6 months. After a follow-up of 2.5 years, there was a trend for more inappropriate shocks with S-ICD (S-ICD, 16 patients vs T-ICD, 7 patients; HR, 2.37; 95% CI, 0.98 to 5.77), but no increase in failed appropriate ICD shocks (HR, 0.61; 95% CI, 0.15 to 2.57), however, this trial was not powered to detect differences in clinical shock outcomes. Although the ATLAS trial found a decreased risk of lead-related perioperative complications, it was underpowered to detect differences in clinical shock outcomes, however, extended follow-up is ongoing.

## Nonrandomized Trials

Several nonrandomized trials and registry studies have reported outcomes for patients receiving a S-ICD, with follow-up periods up to 5.8 years (Table 10).

The Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry (EFFORTLESS) is a multicenter European registry reporting outcomes for patients treated with S-ICD. Several publications from EFFORTLESS, the pivotal trial submitted to the Food and Drug Administration for the investigational device exemption, and other noncomparative studies are described in Table 10. In the EFFORTLESS registry, among 472 enrolled patients, the complication-free rate was 94% at 360 days and there was a 13.1% inappropriate shock rate at 3 years' follow-up. Gold et al (2021) reported 18-month data from the UNTOUCHED study, a multinational, prospective trial designed to assess the performance of the S-ICD in primary prevention patients with a low LVEF and New York Heart Association II/III heart failure or coronary artery disease.<sup>75</sup> At 18 months, the complication-free rate was 92.7% and the inappropriate shock-free rate was 95.9%. One-year data from the S-ICD Post Approval Study and 18-month data from the UNTOUCHED study have been published; these studies are ongoing. The S-ICD System Post-Approval Study (PAS) is a nonrandomized, standard-of-care registry in the United States that has prospectively enrolled and followed S-ICD recipients.<sup>76</sup> Over the first 1 year postimplantation, complications were observed in 119 patients, with a complication-free rate at 1 year of 92.5%. The most common complication was device system infection in 44 of 1,637 patients. This 5-year study is expected to be completed in October 2021, with a total of 1766 participants. Five-year data from the PAS should provide more information on longer-term adverse events such as lead failure and need for device replacement. Gold et al (2022) reported on the 3-year postimplantation follow-up data of the S-ICD PAS.<sup>77</sup> Within 3 years, infection was observed in 55 patients (3.3%) with 69% of infections occurring within 90 days of implantation and the majority (92.7%) within 1 year of implantation. No patient included in the registry had more

than 1 infection and no infections occurred after 2 years in the cohort. The annual post-infection mortality rate was 0.6%. Based on their findings, the authors developed a risk score for likelihood of developing an infection, with diabetes, age  $\geq 55$  years, previous ICD implant, or LVEF  $\leq 30\%$  all identified as contributing risk to S-ICD related infection. This risk score has not been externally validated. The S-ICD PAS study has been completed (NCT01736618) but 5-year results have yet to be published. Five-year data from the PAS should provide more information on longer-term adverse events such as lead failure and need for device replacement.

**Table 10. Summary of Nonrandomized Trials of S-ICD**

Study; Trial	Countries	N	Mean FU	Results	Values
				Outcomes	Values
Burke et al (2020) S-ICD PAS NCT01736618	US	1637	1 y	<ul style="list-style-type: none"> <li>• Complication-free rate at 1 y</li> <li>• Appropriate shock rate at 1 y</li> <li>• Inappropriate shocks at 1 y</li> <li>• Death at 1 y</li> </ul>	<ul style="list-style-type: none"> <li>• 92.5%</li> <li>• 5.3%</li> <li>• 6.5%</li> <li>• 5.4%</li> </ul>
Gold et al (2021) UNTOUCHED NCT02433379	US, Canada, Europe	1111	18 months	<ul style="list-style-type: none"> <li>• Inappropriate shock-free rate at 18 months</li> <li>• Appropriate shock-free rate at 18 months</li> <li>• Complication-free rate at 18 months</li> <li>• Overall survival rate at 18 months</li> </ul>	<ul style="list-style-type: none"> <li>• 94.8%</li> <li>• 94.3%</li> <li>• 92.7%</li> <li>• 94.9%</li> </ul>
Lambiase et al (2014); Olde Nordkamp et al (2015); Boersma et al (2017)- EFFORTLESS S-ICD Registry	10 European countries	985 928 697 498 300 82	3.1 y 1 y 2 y 3 y 4 y 5 y	<ul style="list-style-type: none"> <li>• Complication-rates by 360 d</li> <li>• Inappropriate shocks by 360 d</li> <li>• Complication rates through follow-up</li> <li>• Inappropriate shocks through follow-up</li> <li>• Appropriate shocks through follow-up</li> </ul>	<ul style="list-style-type: none"> <li>• 8.4%</li> <li>• 8.1%</li> <li>• 11.7%</li> <li>• 11.7%</li> <li>• 13.5%</li> </ul>
Weiss et al (2013) IDE study	U.S., U.K., New Zealand, Netherlands	330	11 months	<ul style="list-style-type: none"> <li>• Implanted successfully:</li> <li>• Complication-free at 180 d</li> <li>• Inappropriate shocks</li> <li>• Episodes of discrete spontaneous VT or VF, all successfully converted</li> </ul>	<ul style="list-style-type: none"> <li>• 95%</li> <li>• 99%</li> <li>• 13%</li> <li>• 38</li> </ul>
Burke et al (2015) Boersma et al (2016); Lambiase et al (2016)- EFFORTLESS and IDE studies	Multiple European countries, U.S., New Zealand	882	651 d	<ul style="list-style-type: none"> <li>• Complications within 3 y</li> <li>• Infections requiring device removal or revision</li> <li>• Annual mortality rate</li> <li>• 2-y cumulative mortality</li> <li>• Incidence of therapy for VT or VF: <ul style="list-style-type: none"> <li>○ o1 year</li> <li>○ o2 years</li> <li>○ o3 years</li> </ul> </li> <li>• Incidence of inappropriate shock at 3 y</li> </ul>	<ul style="list-style-type: none"> <li>• 11%</li> <li>• 1.7%</li> <li>• 1.6%</li> <li>• 3.2%</li> <li>• 5.3%</li> <li>• 7.9%</li> <li>• 10.5%</li> <li>• 13.1%</li> </ul>
Bardy et al (2010); Theuns et al (2015)	Europe, New Zealand	55	5.8 y	<ul style="list-style-type: none"> <li>• Devices replaced</li> <li>• Devices explanted</li> <li>• Replaced with T-ICD</li> <li>• Shocks recorded in 16 (29%) patients</li> </ul>	<ul style="list-style-type: none"> <li>• 26 (47%)</li> <li>• 5 (9%)</li> <li>• 4 (7%)</li> <li>• 119</li> </ul>

Olde-Nordkamp et al (2012)	Netherlands	118	18 months	<ul style="list-style-type: none"> <li>• All device-related complications</li> <li>• Infections</li> <li>• Dislodgements of device/leads</li> <li>• Skin erosion</li> <li>• Battery failure</li> <li>• Replaced with T-ICD</li> <li>• Appropriate shocks experienced in 8 patients</li> <li>• Total inappropriate shocks delivered to 15 (13%) patients</li> <li>• Deaths (cancer, progressive heart failure)</li> </ul>	<ul style="list-style-type: none"> <li>• 14%</li> <li>• 5.9%</li> <li>• 3.3%</li> <li>• 1.7%</li> <li>• 1.7%</li> <li>• 1 (0.8%)</li> <li>• 45</li> <li>• 33</li> <li>• 2</li> </ul>
----------------------------	-------------	-----	-----------	--	--

FU: follow-up; S-ICD: subcutaneous implantable cardioverter defibrillator; T-ICD: transvenous implantable cardioverter defibrillator; VF: ventricular fibrillation; VT: ventricular tachycardia.

### Section Summary: Subcutaneous-Implantable Cardioverter Defibrillators in Patients with a Contraindication to a Transvenous Implantable Cardioverter Defibrillator

An RCT found that S-ICD significantly decreases the risk of lead-related perioperative complications compared to T-ICD. However, this study was not powered to detect differences in the rates of failed shocks or inappropriate shocks and an extension study is ongoing. Nonrandomized studies have suggested that S-ICDs are as effective as T-ICDs at terminating laboratory-induced ventricular arrhythmias. Data from large patient registries have suggested that S-ICDs are effective at terminating ventricular arrhythmias when they occur. Given the need for cardioverter defibrillation for SCD risk in this population, with the assumption that appropriate shocks are life-saving, these rates suggest S-ICDs, in patients with contraindication to T-ICD, are likely improvements over medical management alone.

### Subcutaneous Implantable Cardioverter Defibrillators in Individuals with No Contraindication to a Transvenous Implantable Cardioverter Defibrillator

#### Review of Evidence

#### Randomized Controlled Trials

The Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy (PRAETORIAN) trial was a noninferiority RCT that compared S-ICD to T-ICD in 849 patients with an indication for ICD but no indication for pacing (Table 11).<sup>87</sup> The trial is the only RCT on the effect of an S-ICD with health outcomes. Patients were eligible if they were 18 years and older with a class I or II a indication for ICD therapy for primary or secondary prevention, according to professional society guidelines, and no indication for pacing. The median age of enrolled patients was 63 years (interquartile range, 55 to 70). Most enrolled patients were diagnosed with ischemic and nonischemic cardiomyopathy and 19.7% were women. The median left ventricular ejection fraction was 30%.

The primary end point in PRAETORIAN was the composite of device-related complications and inappropriate shocks (see Table 11 for outcome definitions). The trial was designed to test the hypothesis of noninferiority of the S-ICD as compared with the T-ICD with respect to the time from device implantation to the first occurrence of a primary end point event. The primary analysis was the modified intention-to-treat cohort (i.e. patients were analyzed in

accordance with the treatment group to which they were originally assigned, regardless of withdrawals, losses to follow-up or crossovers). Patients who did not receive a device and patients who proved ineligible for one of the treatments due to incomplete or inadequate screening were excluded from this analysis. In the as-treated cohort, patients were analyzed in the group of the specific ICD type which they received at initial implantation regardless of randomization result, withdrawals, losses to follow-up or crossovers. The noninferiority margin for the upper boundary of the 95% confidence interval for the hazard ratio was set at 1.45.

The trial's main results are summarized in Tables 12-14. The S-ICD was noninferior to the T-ICD on the composite endpoint of device-related complications and inappropriate shocks. The hazard ratio for the primary end point was 0.99 (95% confidence interval [CI], 0.71 to 1.39; noninferiority margin, 1.45; P =.01 for noninferiority; P =.95 for superiority). Results for the modified ITT analysis and as-treated analysis did not differ. There were more device related complications in the T-ICD group and more inappropriate shocks in the S-ICD group, but the trial was not powered for these endpoints. Secondary endpoints and mortality results are summarized in Table 13. There were more deaths from any cause in the S-ICD group than in the T-ICD group (16.4% vs 13.1%; hazard ratio 1.23; 95% CI, 0.89 to 1.70), but the number of sudden cardiac deaths did not differ between groups (18 in each group). There were more appropriate shocks in the S-ICD group (19.2% vs 11.5%; hazard ratio 1.52; 95% CI 1.08 to 2.12). Other secondary endpoints did not differ between the groups.

While the rate of sudden cardiac death in the PRAETORIAN trial was low (18 patients in each group), the number of overall deaths was 151, and actually occurred more frequently than the composite outcome (Table 13). The hazard ratio for all-cause mortality was 1.23 (95% CI, 0.89 to 1.70). The PRAETORIAN trial investigators conducted competing risks analyses to account for discontinuation of follow-up before the primary end point had occurred in (1) the modified ITT population with competing risk of death, and (2) the true ITT population with competing risk of death and discontinuation of follow-up. These analyses led to consistent estimates of the hazard ratio (and 95% confidence interval) for the primary end point.

Device and lead complications occurred more frequently in the T-ICD group (Table 14).

**Table 11. PRAETORIAN Trial Characteristics**

Study	Countries	Sites	Dates	Participants	Interventions		Primary Endpoint Definitions
PRAETORIAN Knops et al (2020)					Active	Comparator	
	Europe (92.4%) and US	39	March 2011 through January 2017	Eligibility: 18 years and older Class I or IIa indication for ICD therapy for primary or secondary prevention, according to professional	S-ICD (n = 426)	T-ICD (n = 423)	Composite of device- related complications and inappropriate shocks. Inappropriate shocks were defined as shock therapy for anything else but VF or VT. For example, supraventricular tachycardia with fast ventricle response

				<p>society guidelines. Exclusions: Previous ICD implantation, unsuitability for S-ICD therapy according to QRS-T-wave sensing analysis, and indications for either bradycardia pacing or biventricular pacing.</p>			<p>(including sinus tachycardia and atrial fibrillation), T-wave oversensing, detection of physiological- or other non-cardiac activity and lead- or device failure. Complications included:</p> <ul style="list-style-type: none"> <li>• device infection that led to the extraction of the lead or generator;</li> <li>• pocket hematoma that led to drainage, blood transfusion, or prolongation of hospitalization;</li> <li>• device-related thrombotic events;</li> <li>• pneumothorax or hemothorax that led to intervention or prolongation of hospitalization;</li> <li>• cardiac perforation or tamponade;</li> <li>• lead repositioning or replacement;</li> <li>• other complications related to the lead or generator that led to medical or surgical intervention.</li> </ul>
--	--	--	--	--	--	--	---

ICD: implantable cardioverter defibrillator; PRAETORIAN: Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy

**Table 12. PRAETORIAN Trial Results-Primary composite Endpoint and Components**

Study	Endpoint (4-year cumulative incidence)	S-ICD (n = 426)	T-ICD (n = 423)	Hazard Ratio (95% CI)
PRAETORIAN	Primary composite endpoint	68 (15.1%)	68 (15.7%)	0.99 (0.71 to 1.39) p =.01 for noninferiority; p =.95 for superiority

Knops et al (2020)	(modified ITT analysis)			
	Device-related complication	31 (5.9%)	44 (9.8%)	0.69 (0.44 to 1.09)
	Inappropriate shock	41 (9.7%)	29 (7.3%)	1.43 (0.89 to 2.30)
	Primary composite endpoint (as-treated analysis)	68/428 (15.9%)	68/421 (16.2%)	0.98 (0.70 to 1.37)

CI: confidence interval; ICD: implantable cardioverter defibrillator; ITT: intention-to-treat; PRAETORIAN: Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy

**Table 13. PRAETORIAN Trial Results-Secondary Endpoints**

Study	End Point	S-ICD (N=426)	T-ICD (N=423)	Hazard Ratio (95% CI)
PRAETORIAN				
Knops et al (2020)	Death from any cause	83 (16.4%)	68 (13.1%)	1.23 (0.89 to 1.70)
	Sudden cardiac death	18 (4.2%)	18 (4.3%)	
	Other cardiovascular death	34 (8.0%)	28 (6.6%)	
	Noncardiovascular death	31 (7.3%)	22 (5.2%)	
	Appropriate shock therapy	83 (19.2%)	57 (11.5%)	1.52 (1.08 to 2.12)
	Antitachycardia pacing (appropriate)	6 (0.6%)	54 (12.9%)	
	Antitachycardia pacing (inappropriate)	1 (0.3%)	30 (7.2%)	
	Major adverse cardiac event	64 (13.3%)	80 (16.4%)	0.80 (0.57 to 1.11)
	Hospitalization for heart failure	79 (17.4%)	74 (16.1%)	1.08 (0.79 to 1.49)
	Crossover to other study device	18 (4.3%)	11 (2.7%)	1.64 (0.77 to 3.47)

CI: confidence interval; ICD: implantable cardioverter defibrillator; PRAETORIAN: Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy

**Table 14. PRAETORIAN Trial Results-Specific Complications**

Study	Endpoint	S-ICD (N=426)	T-ICD (N=423)
-------	----------	---------------	---------------

PRAETORIAN			
Knops et al (2020) <sup>87</sup> .	Complications within the first 30 days	3.8%	4.7%
	Lead-related complications	1.4%	6.6%
	Device-related complications	31 (5.9%)	44 (9.8%)
	Infection	4 (1 lead-related)	8 (5 lead-related)
	Bleeding	8	2
	Thrombotic event	1	2
	Pneumothorax	0	4
	Lead perforation	0	4
	Tamponade	0	2
	Lead repositioning	2	7
	Other lead or device complication	19	20
	Lead replacement	3	9
	Device malfunction	4	6
	Sensing issues	4	0
	Pacing indication	5	1
	Implantation failure	0	3
	Defibrillation test failure	3	0
	Pain or discomfort	2	3

CI: confidence interval; ICD: implantable cardioverter defibrillator; Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy

Study relevance, design and conduct limitations of PRAETORIAN are summarized in Tables 15 and 16. The choice of a composite primary endpoint poses several challenges to interpreting the results of PRAETORIAN. In PRAETORIAN, the components of the composite endpoint were discordant; device-related complications were expected to favor S-ICD and inappropriate shocks were expected to favor T-ICD. The timing of the components of the composite outcome assessment is important in interpreting the study results and explaining expected treatment results to patients. Early benefit could favor one treatment over another, and results could change with longer follow-up. This is an important point to consider when assessing complications such as lead failure, which continue to increase over the life of the device. Additionally, because the composite was not used in earlier trials of the active comparator, there is no historical data on which to derive the expected performance of the active control. The inappropriate shock rate was based on results from the MADIT-RT trial, which compared programmed high-rate or delayed T-ICD therapy, and the expected rate of complications was based on results from MADIT-RT and the SCD-HeFT trial, which compared amiodarone to T-ICD. To estimate the expected event rate in PRAETORIAN, the researchers combined these two endpoints to arrive at the expected 17.2% event rate for the composite primary outcome. The study authors do not cite any previous RCTs that used the composite endpoint of complications and inappropriate shocks. All-cause mortality was a primary endpoint in several previous RCTs of T-ICD. However, the PRAETORIAN trial protocol (2012)



noted that all-cause mortality was not chosen as the primary endpoint because “mortality event rates in both groups are presumed to be low, leading to an extremely large trial size if this would serve as a primary endpoint.” The protocol also states that safety and efficacy of the S-ICD have been demonstrated in earlier trials and that the composite endpoint was “preferred above all-cause mortality, as practical, reasonably achievable, and pertinent to most cardiologists.”

Another major limitation of PRAETORIAN was that the median 48-month followup was not long enough to determine complications over the life of the device. In fact, the PRAETORIAN study authors note in their discussion, “longer-term follow-up of this cohort will be important because the incidence of lead-related complications increases over time with the transvenous ICD and because battery longevity is a limiting factor for the subcutaneous ICD.” Five-year data from the S-ICD PAS should provide more information on longer-term adverse events such as lead failure and need for device replacement.

Quality of life data from PRAETORIAN was collected but has not yet been published. This data could shed light on the relative importance to patients of adverse events such as inappropriate shocks and device replacement, especially if quality of life data were reported by subgroups of patients who experienced shocks. For example, these data might indicate that inappropriate shocks are so distressing to patients that they outweigh any potential benefits of S-ICDs.

Finally, the under enrollment of women in the trial (19.7%) potentially limits the applicability of its results, although a subgroup analysis by sex was consistent with the primary analysis on the composite endpoint (Hazard Ratio in women 0.65; 95% CI 0.28 to 1.47).

**Table 15. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Duration of Follow-up <sup>e</sup>
PRAETORIAN Knops et al (2020) <sup>87</sup> .	4. Women underenrolled (19.7%)			6. Composite endpoint with discordant outcomes	2. 4-year median follow-up not sufficient to assess complications over the life of the device

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 16. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
PRAETORIAN Knops et al (2020) <sup>87</sup> .		2. Clinical-events committee was not	2. Quality of life data collected			5. Rationale for choice of noninferiority margin unclear

		blinded to treatment assignment	but not yet published.			
--	--	---------------------------------	------------------------	--	--	--

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

## Comparative Observational Studies

Several observational studies have directly compared T-ICD to S-ICD. These studies are briefly described in Table 17. All studies were performed in the U.S. and/or Europe.

Nonrandomized controlled studies have reported success rates in terminating laboratory-induced VF that are similar to T-ICD. However, there is scant evidence on comparative clinical outcomes of both types of ICD over longer periods. Adverse event rates are uncertain, with variable rates reported.

**Table 17. Summary of Observational Studies of S-ICD and T-ICD**

Study	Study Type	N	Follo w-Up	Results			
				Outcomes	T-ICD	S-ICD	DC T-ICD
Mithani et al (2018)	Matching based on dialysis status, sex, age	182 (91 matched pairs)	180 d	<ul style="list-style-type: none"> <li>Inappropriate shocks</li> <li>Infection requiring explant</li> <li>Death from all causes</li> <li>Total with adverse event or death</li> </ul>	<ul style="list-style-type: none"> <li>2.2 %</li> <li>1.1 %</li> <li>2.2 %</li> <li>7.7 %</li> </ul>	<ul style="list-style-type: none"> <li>1.1 %</li> <li>3.3 %</li> <li>2.2 %</li> <li>5.5 %</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
Honarbash et al (2017)	Propensity matched case-control	138 (69 matched pairs)	32 mo <sup>a</sup>	<ul style="list-style-type: none"> <li>Total device-related complications</li> <li>Infections</li> <li>Inappropriate shocks</li> <li>Failure to cardiovert VA</li> </ul>	<ul style="list-style-type: none"> <li>29%</li> <li>5.8 %</li> <li>8.7 %</li> <li>1.4 %</li> </ul>	<ul style="list-style-type: none"> <li>9%</li> <li>1.4 %</li> <li>4.3 %</li> <li>1.4 %</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
Kobe et al (2017)	Sex- and age-matched case-control	120 (60 pairs); 84 pairs analyzed	942 d vs. 622 d	<ul style="list-style-type: none"> <li>Posttraumatic stress disorder</li> <li>Major depression</li> <li>SF-12 physical</li> </ul>	<ul style="list-style-type: none"> <li>14.3 %</li> <li>9.5 %</li> <li>40</li> <li>52</li> </ul>	<ul style="list-style-type: none"> <li>14.3 %</li> <li>4.8 %</li> <li>47</li> <li>52</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>

				<ul style="list-style-type: none"> <li>well-being score</li> <li>SF-12 mental well-being score</li> </ul>			
Pedersen et al (2016)	Retrospective analysis of propensity-matched cohort	334 (167 matched pairs)	6 mo	<ul style="list-style-type: none"> <li>SF-12 physical well-being score</li> <li>SF-12 mental well-being score</li> </ul>	<ul style="list-style-type: none"> <li>43</li> <li>45</li> </ul>	<ul style="list-style-type: none"> <li>44</li> <li>45</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
Brouwer et al (2016)	Retrospective analysis of propensity-matched cohort	280 (140 matched pairs)	5 y	<ul style="list-style-type: none"> <li>Overall complications</li> <li>Lead complications</li> <li>Non-lead complications</li> <li>Infections</li> <li>Appropriate ICD intervention (HR, 2.4; 95% CI, NR; p=.01)</li> <li>Inappropriate ICD intervention (HR, 1.3; 95% CI, NR; p=.42)</li> <li>Survival</li> </ul>	<ul style="list-style-type: none"> <li>18%</li> <li>11.5%</li> <li>2.2%</li> <li>3.6%</li> <li>31%</li> <li>30%</li> <li>95%</li> </ul>	<ul style="list-style-type: none"> <li>14%</li> <li>0.8%</li> <li>9.9%</li> <li>4.1%</li> <li>17%</li> <li>21%</li> <li>96%</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
Friedman et al (2016)	Retrospective analysis of propensity-matched cohort from NCDR for ICD	5760 (1920 matched, groups)	NR	<ul style="list-style-type: none"> <li>Any in-hospital complication</li> <li>Deaths</li> <li>Infections</li> <li>Lead dislodgements</li> <li>Pneumothorax</li> </ul>	<ul style="list-style-type: none"> <li>0.6%</li> <li>0.1%</li> <li>0%</li> <li>0.2%</li> <li>0.2%</li> </ul>	<ul style="list-style-type: none"> <li>0.9%</li> <li>0.2%</li> <li>0.05%</li> <li>0.1%</li> <li>0%</li> </ul>	<ul style="list-style-type: none"> <li>1.5%</li> <li>0.05%</li> <li>0.1%</li> <li>0.6%</li> <li>0.3%</li> </ul>
Kobe et al (2013)	Sex- and age-matched case-control	138 (69 matched pairs)	217 d <sup>a</sup>	<ul style="list-style-type: none"> <li>Pericardial effusion</li> <li>Successful termination of induced VF</li> </ul>	<ul style="list-style-type: none"> <li>1</li> <li>91%</li> <li>9</li> <li>3</li> </ul>	<ul style="list-style-type: none"> <li>0</li> <li>90%</li> <li>3</li> <li>5</li> </ul>	

				<ul style="list-style-type: none"> <li>• Appropriate shocks</li> <li>• Inappropriate shocks</li> </ul>			
--	--	--	--	--	--	--	--

CI: confidence interval; DC: dual chamber; HR: hazard ratio; ICD: implantable cardioverter defibrillator; NCDR: National Cardiovascular Data Registry; NR: not reported; SF-12: 12-Item Short-Form Health Survey; S-ICD: subcutaneous implantable cardioverter defibrillator; T-ICD: transvenous implantable cardioverter defibrillator; VA: ventricular arrhythmia; VF: ventricular fibrillation.

<sup>a</sup> Mean.

### **Section Summary: Subcutaneous Implantable Cardioverter Defibrillators In Patients With No Contraindications to a Transvenous Implantable Cardioverter Defibrillator**

The PRAETORIAN trial is the only RCT on the effect of an S-ICD with health outcomes. PRAETORIAN found that S-ICD was noninferior to T-ICD on a composite outcome of complications and inappropriate shock at 48 months (Hazard Ratio 0.99; 95% confidence interval, 0.71 to 1.39; noninferiority margin, 1.45;  $P = .01$  for noninferiority;  $P = .95$  for superiority). There were more device related complications in the T-ICD group and more inappropriate shocks in the S-ICD group, but the trial was not powered for these endpoints. There is uncertainty over the applicability and interpretation of PRAETORIAN based on the choice of a composite outcome with discordant results, unclear rationale for choice of the noninferiority margin, inadequate length of follow-up to determine rates of complications, and lack of reporting of quality of life data. Comparative observational studies are insufficient to draw conclusions on whether there are small differences in efficacy between the two types of devices, and reported variable adverse event rates. Ongoing studies could provide additional evidence on complications and device safety over the longer term.

### **Substernal Extravascular ICD**

Another extravascular ICD, the substernal ICD, is being studied for its safety and efficacy. This device, like the S-ICD®, is a device that does not use transvenous leads. Instead, this device uses a lead that is placed under the sternum, outside of the heart and veins. The system is purported to offer anti-tachycardia pacing (ATP), pause prevention pacing, and a device similar in size, shape, and battery longevity to transvenous ICDs. Using a minimally invasive approach, the device is implanted below the left armpit (in the left mid-axillary region).

Friedman et al (2022) conducted a prospective, single-group, nonrandomized, premarket global clinical study involving patients with a class I or IIa indication for an ICD, all of whom received an extravascular ICD system. The primary efficacy end point was successful defibrillation at implantation. The efficacy objective would be met if the lower boundary of the one-sided 97.5% confidence interval for the percentage of patients with successful defibrillation was greater than 88%. The primary safety end point was freedom from major system- or procedure-related complications at 6 months. The safety objective would be met if the lower boundary of the one-sided 97.5% confidence interval for the percentage of patients free from such complications was greater than 79%. A total of 356 patients were enrolled, 316 of whom had an implantation attempt. Among the 302 patients in whom ventricular arrhythmia could be induced and who completed the defibrillation testing protocol, the percentage of patients with successful defibrillation was 98.7% (lower boundary of the one-sided 97.5% confidence interval [CI], 96.6%;  $P < 0.001$  for the comparison with the performance goal of 88%); 299 of 316 patients (94.6%) were discharged with a working ICD system. The Kaplan–Meier estimate of the percentage of patients free from major system- or procedure-related complications at 6 months was 92.6% (lower boundary of the one-sided 97.5% CI, 89.0%;

P<0.001 for the comparison with the performance goal of 79%). No major intraprocedural complications were reported. At 6 months, 25 major complications were observed, in 23 of 316 patients (7.3%). The success rate of antitachycardia pacing, as assessed with generalized estimating equations, was 50.8% (95% CI, 23.3 to 77.8). A total of 29 patients received 118 inappropriate shocks for 81 arrhythmic episodes. Eight systems were explanted without extravascular ICD replacement over the 10.6-month mean follow-up period.

### **Section Summary: Substernal Extravascular ICD**

Only one prospective, single-group, nonrandomized, premarket global clinical study is available for review. The evidence is inadequate to determine the impact of this technology on the net health outcome.

## **SUMMARY OF EVIDENCE**

### **Transvenous ICDs**

In individuals who have a high risk of sudden cardiac death (SCD) in adulthood due to ischemic or nonischemic cardiomyopathy (NICM) who receive transvenous implantable cardioverter defibrillator (T-ICD) placement for primary prevention, the evidence includes multiple well-designed well-conducted randomized controlled trials (RCTs) and systematic reviews of these trials. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related morbidity and mortality. Multiple, well-done, RCTs have demonstrated a benefit in overall mortality for patients with ischemic cardiomyopathy and reduced ejection fraction. RCTs of early ICD implantation following recent myocardial infarction (MI) do not support a benefit for immediate implantation versus delayed implantation for at least 40 days. For NICM, there is less clinical trial evidence, but pooled estimates of available evidence of RCTs enrolling patients with NICM, and from subgroup analysis of RCTs with mixed populations supports a survival benefit for this group. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a high risk of SCD due to hypertrophic cardiomyopathy in adulthood who receive T-ICD placement for primary prevention, the evidence includes several large registry studies. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related morbidity and mortality. In these studies, the annual rate of appropriate ICD discharge ranged from 3.6% to 5.3%. Given the long-term high risk of patients with HCM for SCD risk, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence for the use of ICDs in patients with HCM. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

In individuals who have a high risk of SCD due to an inherited cardiac ion channelopathy who receive T-ICD placement for primary prevention, the evidence includes small cohort studies of patients with these conditions treated with ICDs. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related morbidity and mortality. The limited available evidence for patients with long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and Brugada syndrome (BrS) reports high rates of appropriate shocks. No studies were identified on the use of ICDs for patients with short QT syndrome (SQTS). Studies comparing outcomes between patients treated and untreated with ICDs are not available. However, given the relatively small patient populations and the

high risk of cardiac arrhythmias, clinical trials are unlikely. Given the long-term high risk of patients with inherited cardiac ion channelopathy for SCD risk, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence for the use of T-ICDs in patients with inherited cardiac ion channelopathy. The evidence is insufficient to determine that the technology results in a meaningful improvement in the net health outcomes.

For individuals who have a high risk of SCD due to cardiac sarcoid who receive T-ICD placement for primary prevention, the evidence includes small cohort studies of patients with cardiac sarcoid treated with ICDs who received appropriate shocks. Studies comparing outcomes between patients treated and untreated with ICDs are not available. However, given the relatively small number of patients with cardiac sarcoid (5% of those with systemic sarcoidosis), clinical trials are unlikely. Given the long-term high risk of SCD in patients with cardiac sarcoid, with the assumption that appropriate shocks are life-saving, these studies are considered adequate evidence to support the use of T-ICDs in patients with cardiac sarcoid who have not responded to optimal medical therapy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have who have experienced symptomatic life-threatening sustained VT or VF or have been resuscitated from sudden cardiac arrest (secondary prevention) who receive transvenous ICD (T-ICD) placement, the evidence includes multiple well-designed, well-conducted randomized controlled trials (RCTs) and systematic reviews of these trials. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related morbidity and mortality. Systematic reviews of RCTs demonstrate a 25% reduction in mortality for ICD compared to medical therapy. Analysis of data from a large administrative database confirms that this mortality benefit is generalizable to the clinical setting. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

### **Subcutaneous ICDs**

For individuals who have need for a cardioverter defibrillator and contraindication to transvenous ICD but no indications for antibradycardia pacing and no antitachycardia pacing-responsive arrhythmias who receive S-ICD placement, the evidence includes nonrandomized studies and case series. Relevant outcomes are overall survival, morbid events, quality of life, and treatment-related morbidity and mortality. Nonrandomized controlled studies have reported success rates in terminating laboratory-induced ventricular fibrillation that are similar to T-ICD. Case series have reported high rates of detection and successful conversion of ventricular tachycardia, and inappropriate shock rates in the range reported for T-ICD. Given the need for cardioverter defibrillation for SCD risk in this population, with the assumption that appropriate shocks are life-saving, these rates are considered adequate evidence for the use of S-ICDs in patients with contraindication to T-ICD. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who need an ICD and have no indications for antibradycardia pacing or anti-tachycardia pacing-responsive arrhythmias and have no contraindication to a T-ICD, who receive S-ICD placement, the evidence includes 1 RCT, nonrandomized studies and case series. Relevant outcomes are OS, morbid events, quality of life, and treatment-related mortality and morbidity. The PRAETORIAN (Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) trial is the

only RCT on the effect of an S-ICD with health outcomes. PRAETORIAN found that S-ICD was noninferior to T-ICD on a composite outcome of complications and inappropriate shock at 48 months (Hazard Ratio 0.99; 95% confidence interval , 0.71 to 1.39; noninferiority margin, 1.45; P =.01 for noninferiority; P =.95 for superiority). There were more device related complications in the T-ICD group and more inappropriate shocks in the S-ICD group, but the trial was not powered for these endpoints. There is uncertainty over the applicability and interpretation of PRAETORIAN based on the choice of a composite outcome with discordant results, unclear rationale for choice of the noninferiority margin, inadequate length of follow-up to determine rates of complications, and lack of reporting of quality of life data. Comparative observational studies are insufficient to draw conclusions on whether there are small differences in efficacy between the two types of devices, and reported variable adverse event rates. Ongoing studies could provide additional evidence on complications and device safety over the longer term. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Substernal Extravascular ICD**

The substernal ICD system is investigational and is not yet FDA approved for sale or distribution in the United States. The Extravascular Implantable Cardioverter Defibrillator Pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. It enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand, and results were published in The New England Journal of Medicine. Medtronic has received CE (Conformité Européenne) Mark for the Aurora™ EV ICD system, and has secured FDA approval to conduct a Continued Access Study while the agency reviews the company's related pre-market device application. This evidence is inadequate to determine the impact of this technology on the net health outcome. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

## **SUPPLEMENTAL INFORMATION**

### **Clinical Input Received through Physician Specialty Societies and Academic Medical Centers**

#### **2020 Medical Advisory Panel**

In October 2020, the BCBSA Medical Advisory Panel (MAP) reviewed the evidence for individuals who need an ICD and have no contraindication to transvenous ICD placement and agreed that for this indication, the evidence is insufficient to determine the effects of the technology on health outcomes.

#### **2015 Input**

In response to requests, input was received from 1 physician specialty society (4 responses) and 5 academic medical centers, for a total of 9 responses, while this policy was under review in 2015 with a focus on the use of ICDs as primary prevention for cardiac ion channelopathies and on the use of the S-ICD. Reviewers generally indicated that an ICD should be considered medically necessary for primary prevention of ventricular arrhythmias in both adults and children with a diagnosis of long QT syndrome (LQTS), Brugada syndrome (BrS), short QT syndrome (SQTS), and catecholaminergic polymorphic ventricular tachycardia (CPVT). Reviewers generally indicated that the S-ICD should be considered medically necessary,

particularly for patients with indications for an ICD but who have difficult vascular access or have had T-ICD lead explantation due to complications.

## 2011 Input

For most policy indications, including pediatric indications, there was agreement from those providing input. On the question of timing of ICD implantation, input was mixed, with some commenting about the potential role of early implantation in selected patients. Reviewers indicated that a waiting period of 9 months for patients with nonischemic cardiomyopathy was not supported by the available evidence or consistent with the prevailing practice patterns in academic medical centers. Specialty society input emphasized the difficulty of prescribing strict timeframes given the uncertainty of establishing the onset of cardiomyopathy and the inability to risk stratify patients based on time since onset of cardiomyopathy.

## PRACTICE GUIDELINES AND POSITION STATEMENTS

### American Heart Association, American College of Cardiology, and Heart Failure Society of America (2022)

In 2022, the American Heart Association, American College of Cardiology, and the Heart Failure Society of America released a guideline for the management of heart failure.<sup>95</sup> This guideline includes ICD recommendations which are summarized in Table 18.

**Table 18. Guideline for the Management of Heart Failure - Recommendations for ICDs**

Recommendation	COR	LOE
"In patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF ≤35% and NYHA class I or II symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for >1 year, ICD therapy is recommended for primary prevention of SCD to reduce total mortality."	1	A
"A transvenous ICD provides high economic value in the primary prevention of SCD particularly when the patient's risk of death caused by ventricular arrhythmia is deemed high and the risk of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient's burden of comorbidities and functional status."		A
"In patients at least 40 days post-MI with LVEF ≤30% and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for >1 year, ICD therapy is recommended for primary prevention of SCD to reduce total mortality."	1	B-R
"In patients with genetic arrhythmogenic cardiomyopathy with high-risk features of sudden death, with EF ≤45%, implantation of ICD is reasonable to decrease sudden death."	2a	B-NR
"For patients whose comorbidities or frailty limit survival with good functional capacity to <1 year, ICD and CRT-D are not indicated."	No benefit	C-LD

A: high; B-NR: moderate, non-randomized; B-R: moderate, randomized; C-LD: limited data; COR: class of recommendation; CRT-D: cardiac resynchronization therapy with defibrillation; DCM: dilated cardiomyopathy; EF: ejection fraction; GDMT: guideline-directed management and therapy; ICD: implantable cardioverter defibrillator; LOE: level of evidence; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NYHA: New York Heart Association; SCD: sudden cardiac death.

### American Heart Association/American College of Cardiology et al - Heart Failure (2022)

In 2022, the American Heart Association (AHA), American College of Cardiology (ACC), and the Heart Failure Society of America released a guideline for the management of heart failure.<sup>95</sup> This guideline includes ICD recommendations which are summarized in Table 18.

**Table 18. Guideline for the Management of Heart Failure - Recommendations for ICDs**



Recommendation	COR	LOE
"In patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF $\leq$ 35% and NYHA class I or II symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for >1 year, ICD therapy is recommended for primary prevention of SCD to reduce total mortality."	1	A
"A transvenous ICD provides high economic value in the primary prevention of SCD particularly when the patient's risk of death caused by ventricular arrhythmia is deemed high and the risk of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient's burden of comorbidities and functional status."		A
"In patients at least 40 days post-MI with LVEF $\leq$ 30% and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for >1 year, ICD therapy is recommended for primary prevention of SCD to reduce total mortality."	1	B-R
"In patients with genetic arrhythmogenic cardiomyopathy with high-risk features of sudden death, with EF $\leq$ 45%, implantation of ICD is reasonable to decrease sudden death."	2a	B-NR
"For patients whose comorbidities or frailty limit survival with good functional capacity to <1 year, ICD and CRT-D are not indicated."	No benefit	C-LD

A: high; B-NR: moderate, non-randomized; B-R: moderate, randomized; C-LD: limited data; COR: class of recommendation; CRT-D: cardiac resynchronization therapy with defibrillation; DCM: dilated cardiomyopathy; EF: ejection fraction; GDMT: guideline-directed management and therapy; ICD: implantable cardioverter defibrillator; LOE: level of evidence; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NYHA: New York Heart Association; SCD: sudden cardiac death.

## American Heart Association (AHA), American College of Cardiology (ACC) et al— Hypertrophic Cardiomyopathy (2020)

In 2020, the AHA and ACC published a joint Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy.<sup>96</sup> Recommendations relevant to this review are summarized in Table 19.

**Table 19. Patient Selection For ICD Placement In High-Risk Patients With Hypertrophic Cardiomyopathy**

Recommendations	COR	LOE
For patients with HCM, and previous documented cardiac arrest or sustained ventricular tachycardia, ICD placement is recommended.	1	B-NR
For adult patients with HCM with 1 or more major risk factors for SCD, it is reasonable to offer an ICD.	2a	B-NR
For children with HCM who have 1 or more conventional risk factors, ICD placement is reasonable after considering the relatively high complication rates of long-term ICD placement in younger patients.	2a	B-NR
For patients 16 years and older with HCM and 1 or more major SCD risk factors, discussion of the estimated 5-year sudden death risk and mortality rates can be useful during the shared decision-making process for ICD placement.	2a	B-NR
In patients with HCM without risk factors, ICD placement should not be performed.	3-HARM	B-NR
In patients with HCM, ICD placement for the sole purpose of participation in competitive athletics should not be performed.	3-HARM	B-NR
In patients with HCM who are receiving an ICD, either a single chamber transvenous ICD or a subcutaneous ICD is recommended after a shared decision-making discussion that takes into consideration patient preferences, lifestyle, and expected potential need for pacing for bradycardia or ventricular tachycardia termination.	1	B-NR

B-NR: moderate, non-randomized; COR: class of recommendation; HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter defibrillator; LOE: level of evidence; SCD: sudden cardiac death.

## American Heart Association/American College of Cardiology et al - Ventricular Arrhythmias and Prevention of Sudden Cardiac Death (2017)

The AHA, ACC, and Heart Rhythm Society (2017) published joint guidelines on the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.<sup>97</sup> This guideline supersedes the 2008 guideline for device-based therapy of cardiac rhythm abnormalities<sup>98</sup>, and the subsequent 2012 focused update.<sup>99</sup> The most up-to-date recommendations on the use of transvenous ICD devices from the 2017 guidelines are presented in Tables 20 to 24. Table 25 summarizes the most up-to-date recommendations regarding S-ICDs.

**Table 20. Recommendations on Use of ICDs as Secondary Prevention of SCD of Ischemic Heart Disease or Nonischemic Cardiomyopathy**

Recommendations	COR	LOE
"In patients with ischemic heart disease, who either survive SCA due to VT/VF or experience hemodynamically unstable VT (LOE: B-R) or stable sustained VT (LOE: B-NR) not due to reversible causes, an ICD is recommended if meaningful survival of greater than 1 year is expected."	I	B-R B-NR
"A transvenous ICD provides intermediate value in the secondary prevention of SCD particularly when the patient's risk of death due to a VA is deemed high and the risk of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient's burden of comorbidities and functional status."		B-R
"In patients with ischemic heart disease and unexplained syncope who have inducible sustained monomorphic VT on electrophysiological study, an ICD is recommended if meaningful survival of greater than 1 year is expected."	1	B-NR
"In patients resuscitated from SCA due to coronary artery spasm in whom medical therapy is ineffective or not tolerated, an ICD is reasonable if meaningful survival of greater than 1 year is expected."	IIa	B-NR
"In patients resuscitated from SCA due to coronary artery spasm, an ICD in addition to medical therapy may be reasonable if meaningful survival of greater than 1 year is expected."	IIb	B-NR
"In patients with NICM who either survive SCA due to VT/VF or experience hemodynamically unstable VT (LOE: B-R) (1-4) or stable VT (LOE: B-NR) (5) not due to reversible causes, an ICD is recommended if meaningful survival of greater than 1 year is expected."	1	B-R B-NR
"In patients with NICM who experience syncope presumed to be due to VA and who do not meet indications for a primary prevention ICD, an ICD or an electrophysiological study for risk stratification for SCD can be beneficial if meaningful survival of greater than 1 year is expected."	11a	B-NR
"In patients with arrhythmogenic right ventricular cardiomyopathy and an additional marker of increased risk of SCD (resuscitated SCA, sustained VT, significant ventricular dysfunction with RVEF or LVEF $\leq$ 35%), an ICD is recommended if meaningful survival of greater than 1 year is expected."	1	B-NR
"In patients with arrhythmogenic right ventricular cardiomyopathy and syncope presumed due to VA, an ICD can be useful if meaningful survival of greater than 1 year is expected."	11a	B-NR

B-NR: moderate, non-randomized; B-R: moderate, randomized; COR: class of recommendation; ICD: implantable cardioverter defibrillator; LOE: level of evidence; LVEF: left ventricular ejection fraction; NICM: nonischemic cardiomyopathy; RVEF: right ventricular ejection fraction; SCA: sudden cardiac arrest; SCD: sudden cardiac death; VA: ventricular arrhythmia; VF: ventricular fibrillation; VT: ventricular tachycardia.

**Table 21. Recommendations on Use of ICDs as a Primary Prevention of Ischemic Heart Disease or Nonischemic Cardiomyopathy**

Recommendation	COR	LOE
"In patients with LVEF of 35% or less that is due to ischemic heart disease who are at least 40 days' post-MI and at least 90 days postrevascularization, and with NYHA class II or III	I	A

HF despite GDMT, an ICD is recommended if meaningful survival of greater than 1 year is expected."		
"In patients with LVEF of 30% or less that is due to ischemic heart disease who are at least 40 days' post-MI and at least 90 days postrevascularization, and with NYHA class I HF despite GDMT, an ICD is recommended if meaningful survival of greater than 1 year is expected."	1	A
"A transvenous ICD provides high value in the primary prevention of SCD particularly when the patient's risk of death due to a VA is deemed high and the risk of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient's burden of comorbidities and functional status."		B-R
"In patients with NSVT due to prior MI, LVEF of 40% or less and inducible sustained VT or VF at electrophysiological study, an ICD is recommended if meaningful survival of greater than 1 year is expected."	1	B-R
"In nonhospitalized patients with NYHA class IV symptoms who are candidates for cardiac transplantation or an LVAD, an ICD is reasonable if meaningful survival of greater than 1 year is expected."	11a	B-NR
"An ICD is not indicated for NYHA class IV patients with medication-refractory HF who are not also candidates for cardiac transplantation, an LVAD, or a CRT defibrillator that incorporates both pacing and defibrillation capabilities."	111a	C-EO
"In patients with NICM, HF with NYHA class II-III symptoms and an LVEF of 35% or less, despite GDMT, an ICD is recommended if meaningful survival of greater than 1 year is expected."	1	A
"In patients with NICM due to a <i>Lamc A/C</i> mutation who have 2 or more risk factors (NSVT, LVEF <45%, nonmissense mutation, and male sex), an ICD can be beneficial if meaningful survival of greater than 1 year is expected."	11a	B-NR
"In patients with NICM, HF with NYHA class I symptoms and an LVEF of 35% or less, despite GDMT, an ICD may be considered if meaningful survival of greater than 1 year is expected."	11b	B-R
"In patients with medication-refractory NYHA class IV HF who are not also candidates for cardiac transplantation, an LVAD, or a CRT defibrillator that incorporates both pacing and defibrillation capabilities, an ICD should not be implanted."	111a	C-EO

A: high; B-NR: moderate, non-randomized; B-R: moderate, randomized; C-EO: consensus of expert opinion; CRT: cardiac resynchronization therapy; COR: class of recommendation; GDMT: guideline-directed management and therapy; HF: heart failure; ICD: implantable cardioverter defibrillator; LOE: level of evidence; LVAD: left ventricular assist device; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NICM: nonischemic cardiomyopathy; NSVT: nonsustained ventricular tachycardia; NYHA: New York Heart Association; SCD: sudden cardiac death; VA: ventricular arrhythmia; VF: ventricular fibrillation; VT: ventricular tachycardia.

<sup>a</sup> No benefit.

**Table 22. Recommendations on Use of ICDs for HCM**

Recommendation	COR	LOE
"In patients with HCM who have survived an SCA due to VT or VF, or have spontaneous sustained VT causing syncope or hemodynamic compromise an ICD is recommended if meaningful survival of greater than 1 year is expected."	I	B-NR
"In patients with HCM and 1 or more of the following risk factors, an ICD is recommended if meaningful survival of greater than 1 year is expected." a. Maximum LV wall thickness $\geq 30$ mm (LOE: B-NR). b. SCD in 1 or more first-degree relatives presumably caused by HCM (LOE: C-LD). c. 1 or more episodes of unexplained syncope within the preceding 6 months (LOE: C-LD).	IIa	B-NR C-LD C-LD
"In patients with HCM who have spontaneous NSVT (LOE: C-LD) or an abnormal blood pressure response with exercise (LOE: B-NR), who also have additional SCD risk modifiers or high risk features, an ICD is recommended if meaningful survival of greater than 1 year is expected."	IIa	B-NR C-LD
"In patients with HCM who have NSVT (LOE: B-NR) or an abnormal blood pressure response with exercise (LOE: B-NR) but do not have any other SCD risk modifiers, and ICD may be considered, but its benefit is uncertain."	IIB	B-NR B-NR
"In patients with an identified HCM genotype in the absence of SCD risk factors, and ICD should not be implanted."	III <sup>a</sup>	B-NR

B-NR: moderate, non-randomized; C-LD: limited data; COR: class of recommendation; HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter defibrillator; LOE: level of evidence; LV: left ventricular; NSVT: nonsustained ventricular tachycardia; SCA: sudden cardiac arrest; SCD: sudden cardiac death; VF: ventricular fibrillation; VT: ventricular tachycardia.  
<sup>a</sup> No benefit.

**Table 23. Recommendations on Use of ICDs for Cardiac Sarcoidosis**

Recommendation	COR	LOE
"In patients with cardiac sarcoidosis who have sustained VT or are survivors of SCA or have an LVEF of 35% or less..."	I	B-NR
"In patients with cardiac sarcoidosis and LVEF greater than 35% who have syncope and/or evidence of myocardial scar by cardiac MRI or position emission tomographic (PET) scan, and/or have an indication for permanent pacing."	IIa	B-NR
"In patients with cardiac sarcoidosis and LVEF greater than 35%, it is reasonable to perform an electrophysiological study and to implant an ICD, if sustained VA is inducible..."	IIa	C-LD
"In patients with cardiac sarcoidosis who have an indication for permanent pacing, implantation of an ICD can be beneficial."	IIa	C-LD

COR: class of recommendation; ICD: implantable cardioverter defibrillator; LOE: level of evidence; LVEF: left ventricular ejection fraction; MRI: magnetic resonance imaging; SCA: sudden cardiac arrest; VA: ventricular arrhythmia.

**Table 24. Recommendations on Use of ICDs for Other Conditions**

Recommendation	COR	LOE
"In patients with HFrEF who are awaiting heart transplant and who otherwise would not qualify for an ICD (e.g., NYHA class IV and/or use of inotropes) with a plan to discharge home, and ICD is reasonable"	IIa	B-NR
"In patients with an LVAD and sustained VA, an ICD can be beneficial."	IIa	C-LD
"In patients with a heart transplant and severe allograft vasculopathy with LV dysfunction, an ICD may be reasonable if meaningful survival of greater than 1 year is expected."	IIb	B-NR
"In patients with neuromuscular disorders, primary and secondary prevention ICDs are recommended for the same indications as for patients with NICM, if meaningful survival of greater than 1 year is expected"	I	B-NR
"In patients with cardiac channelopathy and SCA, an ICD is recommended if meaningful survival of greater than 1 year is expected."	I	B-NR
"In patients with catecholaminergic polymorphic ventricular tachycardia and recurrent sustained VT or syncope, while receiving adequate or maximally tolerated beta blocker, treatment intensification with either combination medication therapy, left cardiac sympathetic denervation, and/or an ICD is recommended."	I	B-NR
"In patients with Brugada syndrome with spontaneous type 1 Brugada electrocardiographic pattern and cardiac arrest, sustained VA or a recent history of syncope presumed due to VA, an ICD is recommended if meaningful survival of greater than 1 year is expected."	I	B-NR
"In patients with early repolarization pattern on ECG and cardiac arrest or sustained VA, an ICD is recommended if meaningful survival of greater than 1 year is expected."	I	B-NR
"In patients resuscitated from SCA due to idiopathic polymorphic VT or VF..."	I	B-NR
"For older patients and those with significant comorbidities, who meet indications for a primary prevention ICD, and ICD is reasonable, if meaningful survival of greater than 1 year is expected."	IIa	B-NR
"In patients with adult congenital heart disease with SCA due to VT or VF in the absence of reversible causes..."	I	B-NR
"In patients with repaired moderate or severe complexity adult congenital heart disease with unexplained syncope and at least moderate ventricular dysfunction or marked hypertrophy, either ICD implantation or an electrophysiological study with ICD implantation for inducible sustained VA is reasonable..."	IIa	B-NR

COR: class of recommendation; ECG: electrocardiogram; HFrEF: heart failure with reduced ejection fraction; ICD: implantable cardioverter defibrillator; LOE: level of evidence; LV: left ventricle; LVAD: left ventricular assist device; LVEF: left ventricular ejection fraction; NICM: nonischemic cardiomyopathy; VA: ventricular arrhythmia; VF: ventricular fibrillation; VT: ventricular tachycardia.

**Table 25. Recommendations on Use of Subcutaneous ICDs**

Recommendation	COR	LOE
"In patients who meet criteria for an ICD who have inadequate vascular access or are at high risk for infection, and in whom pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated, a subcutaneous implantable cardioverter-defibrillator is recommended."	I	B-NR
"In patients who meet indication for an ICD, implantation of a subcutaneous implantable cardioverter-defibrillator is reasonable if pacing for bradycardia or VT termination or as part of CRT is either needed nor anticipated."	IIa	B-NR
In patients with an indication for bradycardia pacing or CRT, or for whom antitachycardia pacing for VT termination is required, a subcutaneous implantable cardioverter-defibrillator should not be implanted."	III <sup>a</sup>	B-NR

CRT: cardiac resynchronization therapy; COR: class of recommendation; ICD: implantable cardioverter defibrillator; LOE: level of evidence; VT: ventricular tachycardia. a Harm.

### Heart Rhythm Society- Arrhythmogenic Cardiomyopathy (2019)

In 2019, the Heart Rhythm Society published a consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.<sup>100</sup> Recommendations related to ICD risk stratification and placement decisions are shown in Table 26.

**Table 26. Recommendations on Risk Stratification and ICD Decisions**

Recommendation	COR <sup>1</sup>	LOE <sup>2</sup>
In individuals with ARVC with hemodynamically tolerated sustained VT, an ICD is reasonable.	IIa	B-NR
ICD implantation is reasonable for individuals with ARVC and three major, two major and two minor, or one major and four minor risk factors for ventricular arrhythmia.	IIa	B-NR
ICD implantation may be reasonable for individuals with ARVC and two major, one major and two minor, or four minor risk factors for ventricular arrhythmia.	IIb	B-NR
In individuals with ACM with LVEF 35% or lower and NYHA class II-III symptoms and an expected meaningful survival of greater than 1 year, an ICD is recommended.	I	B-R
In individuals with ACM with LVEF 35% or lower and NYHA class I symptoms and an expected meaningful survival of greater than 1 year, an ICD is reasonable.	IIa	B-R
In individuals with ACM (other than ARVC) and hemodynamically tolerated VT, an ICD is recommended.	I	B-NR
In individuals with phospholamban cardiomyopathy and LVEF <45% or NSVT, an ICD is reasonable.	IIa	B-NR
In individuals with lamin A/C ACM and two or more of the following: LVEF <45%, NSVT, male sex, an ICD is reasonable.	IIa	B-NR
In individuals with FLNC ACM and an LVEF <45%, an ICD is reasonable.	IIa	C-LD
In individuals with lamin A/C ACM and an indication for pacing, an ICD with pacing capabilities is reasonable.	IIa	C-LD

ACM: arrhythmogenic cardiomyopathy; ARVC: arrhythmogenic right ventricular cardiomyopathy; COR: Class of Recommendation; FLNC: filamin-C; HRS: Heart Rhythm Society; ICD: Implantable cardioverter defibrillator; LOE: Level of Evidence; LVEF: left ventricular ejection fraction; NSVT: nonsustained ventricular tachycardia; NYHA: New York Heart Association; VT: ventricular tachycardia.

<sup>1</sup> Class I: Strong; Class IIa: Moderate; Class IIb: Weak. <sup>2</sup> B-R: Randomized; B-NR: nonrandomized; C-LD: limited data.

### Heart Rhythm Society et al - Inherited Primary Arrhythmia Syndromes (2013)

The Heart Rhythm Society, the European Heart Rhythm Association, and the Asia-Pacific Heart Rhythm Society (2013) issued a consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes, which included

recommendations on ICD use in patients with long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome (Table 27).<sup>101</sup>

**Table 27. Recommendations on ICDs in Inherited Primary Arrhythmia Syndromes**

Recommendation	COR
<i>Long QT syndrome</i>	
ICD implantation is recommended for patients with a diagnosis of LQTS who are survivors of a cardiac arrest.	I
ICD implantation can be useful in patients with a diagnosis of LQTS who experience recurrent syncopal events while on beta-blocker therapy.	IIa
Except under special circumstances, ICD implantation is not indicated in asymptomatic LQTS patients who have not been tried on beta-blocker therapy.	IIIa
<i>Brugada syndrome</i>	
ICD implantation is recommended in patients with a diagnosis of BrS who: <ul style="list-style-type: none"> <li>• Are survivors of a cardiac arrest and/or</li> <li>• Have documented spontaneous sustained VT with or without syncope.</li> </ul>	1
ICD implantation can be useful in patients with a spontaneous diagnostic type I ECG who have a history of syncope judged to be likely caused by ventricular arrhythmias.	IIa
ICD implantation may be considered in patients with a diagnosis of BrS who develop VF during programmed electrical stimulation (inducible patients).	IIb
ICD implantation is not indicated in asymptomatic BrS patients with a drug-induced type I ECG and on the basis of a family history of SCD alone.	IIIa
<i>Catecholaminergic polymorphic ventricular tachycardia</i>	
ICD implantation is recommended for patients with a diagnosis of CPVT who experience cardiac arrest, recurrent syncope or polymorphic/bidirectional VT despite optimal medical management, and/or left cardiac sympathetic denervation.	I
ICD as a stand alone therapy is not indicated in an asymptomatic patient with a diagnosis of CPVT.	IIIa
<i>Short QT syndrome</i>	
ICD implantation is recommended in symptomatic patients with a diagnosis of SQTS who: are survivors of cardiac arrest and/or have documented spontaneous VT with or without syncope.	I
ICD implantation may be considered in asymptomatic patients with a diagnosis of SQTS and a family history of sudden cardiac death.	IIb

BrS: Brugada syndrome; COR: class of recommendation; CPVT: catecholaminergic polymorphic ventricular tachycardia; ECG: electrocardiogram; HRS: Heart Rhythm Society; ICD: implantable cardioverter defibrillator; LQTS: long QT syndrome; SCD: sudden cardiac death; SQTS: short QT syndrome; VF: ventricular fibrillation; VT: ventricular tachycardia.

<sup>a</sup> Not recommended.

### Heart Rhythm Society - Cardiac Sarcoidosis (2014)

In 2014, the Heart Rhythm Society published a consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis, including recommendations for ICD implantation in patients with cardiac sarcoidosis (Table 28).<sup>33</sup> The writing group concluded that although there are few data specific to ICD use in patients with cardiac sarcoidosis, data from the major primary and secondary prevention ICD trials were relevant to this population and recommendations from the general device guideline documents apply to this population.

**Table 28. Recommendations for ICD Implantation in Patients with Cardiac Sarcoidosis**

Recommendation	COR <sup>1</sup>
ICD implantation is recommended in patients with cardiac sarcoidosis and one or more of the following: <ul style="list-style-type: none"> <li>• Spontaneous sustained ventricular arrhythmias, including prior cardiac arrest</li> <li>• LVEF &lt;35%, despite optimal medical therapy and a period of immunosuppression (if there is active inflammation).</li> </ul>	I
ICD implantation <b>can be useful</b> in patients with cardiac sarcoidosis, independent of ventricular function, and one or more of the following: <ul style="list-style-type: none"> <li>• An indication for permanent pacemaker implantation;</li> <li>• Unexplained syncope or near-syncope, felt to be arrhythmic in etiology;</li> </ul>	IIa

<ul style="list-style-type: none"> <li>Inducible sustained ventricular arrhythmias (&gt;30 seconds of monomorphic VT or polymorphic VT) or clinically relevant VF.</li> </ul>	
ICD implantation may be considered in patients with LVEF in the range of 36%–49% and/or an RV ejection fraction <40%, despite optimal medical therapy for heart failure and a period of immunosuppression (if there is active inflammation).	IIb
ICD implantation <b>is not recommended</b> in patients with no history of syncope, normal LVEF/RV ejection fraction, no LGE on CMR, a negative EP study, and no indication for permanent pacing. However, these patients should be closely followed for deterioration in ventricular function. ICD implantation <b>is not recommended</b> in patients with one or more of the following: <ul style="list-style-type: none"> <li>Incessant ventricular arrhythmias;</li> <li>Severe New York Heart Association class IV heart failure.</li> </ul>	III

COR: Class of Recommendation; EP: electrophysiologic; ICD: implantable cardioverter defibrillator; LGE-CMR: late gadolinium-enhanced cardiovascular magnetic resonance; LOE: Level of Evidence; LVEF: left ventricular ejection fraction; RV: right ventricular.

<sup>1</sup>Class I: Strong; Class IIa: Moderate; Class IIb: Weak.

### Pediatric and Congenital Electrophysiology Society et al

The Pediatric and Congenital Electrophysiology Society and Heart Rhythm Society (2014) issued an expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease.<sup>102</sup> The statement made the following recommendations on the use of ICD therapy in adults with congenital heart disease (Table 29).

**Table 29. Recommendations on ICDs in the Management of CHD**

Recommendation	COR	LOE
ICD therapy is indicated in adults with CHD who are survivors of cardiac arrest due to ventricular fibrillation or hemodynamically unstable ventricular tachycardia after evaluation to define the cause of the event and exclude any completely reversible etiology.	I	B
ICD therapy is indicated in adults with CHD and spontaneous sustained ventricular tachycardia who have undergone hemodynamic and electrophysiologic evaluation.	I	B
ICD therapy is indicated in adults with CHD and a systemic left ventricular ejection fraction <35%, biventricular physiology, and NYHA class II or III symptoms.	I	B
ICD therapy is reasonable in selected adults with tetralogy of Fallot and multiple risk factors for sudden cardiac death, such as left ventricular systolic or diastolic dysfunction, nonsustained ventricular tachycardia, QRS duration >180 ms, extensive right ventricular scarring, or inducible sustained ventricular tachycardia at electrophysiologic study.	IIa	B
ICD therapy may be reasonable in adults with a single or systemic right ventricular ejection fraction <35%, particularly in the presence of additional risk factors such as complex ventricular arrhythmias, unexplained syncope, NYHA functional class II or III symptoms, QRS duration >140 ms, or severe systemic AV valve regurgitation.	IIb	C
ICD therapy may be considered in adults with CHD and a systemic ventricular ejection fraction <35% in the absence of overt symptoms (NYHA class I) or other known risk factors.	Ib	C
ICD therapy may be considered in adults with CHD and syncope of unknown origin with hemodynamically significant sustained ventricular tachycardia or fibrillation inducible at electrophysiologic study.	Ib	B
ICD therapy may be considered for nonhospitalized adults with CHD awaiting heart transplantation.	Ib	C
ICD therapy may be considered for adults with syncope and moderate or complex CHD in whom there is a high clinical suspicion of ventricular arrhythmia and in whom thorough invasive and noninvasive investigations have failed to define a cause.	Ib	C
Adults with CHD and advanced pulmonary vascular disease (Eisenmenger syndrome) are generally not considered candidates for ICD therapy.	III <sup>a</sup>	
Endocardial leads are generally avoided in adults with CHD and intracardiac shunts. Risk assessment regarding hemodynamic circumstances, concomitant anticoagulation, shunt closure prior to endocardial lead placement, or alternative approaches for lead access should be individualized.	III <sup>a</sup>	

AV: atrioventricular ; CHD: congenital heart disease; COR: class of recommendation; ICD: implantable cardioverter defibrillator; LOE: level of evidence; NYHA: New York Heart Association.

<sup>a</sup> Not recommended.

In 2021, the Pediatric and Congenital Electrophysiology Society and Heart Rhythm Society also issued an expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients.<sup>103</sup> Table 30 summarizes recommendations for ICD therapy from this statement.

**Table 30. Recommendations for ICD Therapy in Pediatric Patients**

Recommendation	COR	LOE
ICD implantation is indicated for survivors of SCA due to VT/VF if completely reversible causes have been excluded and an ICD is considered to be more beneficial than alternative treatments that may significantly reduce the risk of SCA.	I	B-NR
ICD implantation may be considered for patients with sustained VT that cannot be adequately controlled with medication and/or catheter ablation.	2b	C-EO
ICD therapy may be considered for primary prevention of SCD in patients with genetic cardiovascular diseases and risk factors for SCA or pathogenic mutations and family history of recurrent SCA.	2b	C-EO
ICD therapy is not indicated for patients with incessant ventricular tachyarrhythmias due to risk of ICD storm.	3: Harm	C-EO
ICD therapy is not indicated for patients with ventricular arrhythmias that are adequately treated with medication and/or catheter ablation.	3: Harm	C-LD
ICD therapy is not indicated for patients who have an expected survival <1 year, even if they meet ICD implantation criteria specified in the above recommendations.	3: Harm	C-EO
ICD implantation along with the use of beta-blockade is indicated for patients with a diagnosis of LQTS who are survivors of SCA.	I	B-NR
ICD implantation is indicated in LQTS patients with symptoms in whom beta-blockade is either ineffective or not tolerated and cardiac sympathetic denervation or other medications are not considered effective alternatives.	I	B-NR
ICD therapy may be considered for primary prevention in LQTS patients with established clinical risk factors and/or pathogenic mutations.	2b	C-LD
ICD implantation is not indicated in asymptomatic LQTS patients who are deemed to be at low risk of SCA and have not been tried on beta-blocker therapy.	3: Harm	C-LD
ICD implantation is indicated in patients with a diagnosis of CPVT who experience cardiac arrest or arrhythmic syncope despite maximally tolerated beta-blocker plus flecainide and/or cardiac sympathetic denervation.	I	C-LD
ICD implantation is reasonable in combination with pharmacologic therapy with or without cardiac sympathetic denervation when aborted SCA is the initial presentation of CPVT. Pharmacologic therapy and/or cardiac sympathetic denervation without ICD may be considered as an alternative.	2a	C-LD
ICD therapy may be considered in CPVT patients with polymorphic/bidirectional VT despite optimal pharmacologic therapy with or without cardiac sympathetic denervation.	2b	C-LD
ICD implantation is not indicated in asymptomatic patients with a diagnosis of CPVT.	3: Harm	C-EO
ICD implantation is indicated in patients with a diagnosis of BrS who are survivors of SCA or have documented spontaneous sustained VT.	I	B-NR
ICD implantation is reasonable for patients with BrS with a spontaneous type I Brugada ECG pattern and recent syncope presumed due to ventricular arrhythmias.	2a	B-NR
ICD implantation may be considered in patients with syncope presumed due to ventricular arrhythmias with a type I Brugada ECG pattern only with provocative medications.	2b	C-EO
ICD implantation is not indicated in asymptomatic BrS patients in the absence of risk factors.	3: No benefit	C-EO
ICD implantation is indicated in patients with HCM who are survivors of SCA or have spontaneous sustained VT.	I	B-NR
For children with HCM who have ≥1 primary risk factors, including unexplained syncope, massive left ventricular hypertrophy, nonsustained VT, or family history of early HCM-related	2a	B-NR



SCD, ICD placement is reasonable after considering the potential complications of long-term ICD placement.		
ICD implantation may be considered in patients with HCM without the above risk factors but with secondary risk factors for SCA such as extensive LGE cardiac MRI or systolic dysfunction.	2b	B-NR
ICD implantation is not indicated in patients with an identified HCM genotype in the absence of known pediatric SCA risk factors.	3: Harm	C-LD
ICD implantation is indicated in patients with ACM who have been resuscitated from SCA or sustained VT that is not hemodynamically tolerated.	I	B-NR
For children with HCM who have ≥1 primary risk factors, including unexplained syncope, massive left ventricular hypertrophy, nonsustained VT, or family history of early HCM-related SCD, ICD placement is reasonable after considering the potential complications of long-term ICD placement.	2a	B-NR
ICD implantation may be considered in patients with HCM without the above risk factors but with secondary risk factors for SCA such as extensive LGE cardiac MRI or systolic dysfunction.	2b	B-NR
ICD implantation is not indicated in patients with an identified HCM genotype in the absence of known pediatric SCA risk factors.	3: Harm	C-LD
ICD implantation is indicated in patients with ACM who have been resuscitated from SCA or sustained VT that is not hemodynamically tolerated.	I	B-NR
ICD implantation is reasonable in patients with ACM with hemodynamically tolerated sustained VT, syncope presumed due to ventricular arrhythmia, or an LVEF ≤35%.	2a	B-NR
ICD implantation may be considered in patients with inherited ACM associated with increased risk of SCD based on an assessment of additional risk factors.	2b	C-LD
ICD implantation is indicated in patients with NIDCM who either survive SCA or experience sustained VT not due to completely reversible causes.	I	B-NR
ICD implantation may be considered in patients with NIDCM and syncope or an LVEF ≤35%, despite optimal medical therapy.	2b	C-LD
ICD implantation is not recommended in patients with medication-refractory advanced heart failure who are not cardiac transplantation or left ventricular assist device candidates.	3: Harm	C-EO
ICD therapy is not indicated for patients with advanced heart failure who are urgently listed for cardiac transplantation and will remain in the hospital until transplantation, even if they meet ICD implantation criteria specified in the above recommendations.	3: No benefit	C-EO
ICD implantation is indicated for CHD patients who are survivors of SCA after evaluation to define the cause of the event and exclude any completely reversible causes.	I	B-NR
ICD implantation is indicated for CHD patients with hemodynamically unstable sustained VT who have undergone hemodynamics and EP evaluation.	I	C-LD
ICD implantation is reasonable for CHD patients with systemic LVEF <35% and sustained VT or presumed arrhythmogenic syncope.	2a	C-LD
ICD implantation may be considered for CHD patients with spontaneous hemodynamically stable sustained VT who have undergone hemodynamic and EP evaluation.	2b	C-EO
ICD implantation may be considered for CHD patients with unexplained syncope in the presence of ventricular dysfunction, nonsustained VT, or inducible ventricular arrhythmias at EP study.	2b	C-LD
ICD implantation may be considered for CHD patients with a single or systemic right ventricular ejection fraction ≤35%, particularly in the presence of additional risk factors such as VT, arrhythmic syncope, or severe systemic AV valve insufficiency.	2b	C-EO

ACM: arrhythmogenic cardiomyopathy; AV: atrioventricular; B-NR: moderate, non-randomized; BrS: Brugada syndrome; C-EO: consensus of expert opinion; CHD: congenital heart disease; C-LD: limited data; COR: class of recommendation; CPVT: catecholaminergic polymorphic ventricular tachycardia; ECG: electrocardiogram; EP: electrophysiology; HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter defibrillator; LGE: late gadolinium-enhanced; LOE: level of evidence; LQTS: long QT syndrome; LVEF: left ventricular ejection fraction; MRI: magnetic resonance imaging; NIDCM: non-ischemic dilated cardiomyopathy; SCA: sudden cardiac arrest; SCD: sudden cardiac death; VF: ventricular fibrillation; VT: ventricular tachycardia.

## ONGOING AND UNPUBLISHED CLINICAL TRIALS

Some currently unpublished trials that might influence this review are listed in Table 34.

**Table 31. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
NCT02845531	Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death (VARIANT ICD)	140	Jun 2023
NCT01296022 <sup>a</sup>	Randomized Trial to Study the Efficacy and Adverse Effects of the Subcutaneous and Transvenous Implantable Cardioverter Defibrillator (ICD) in Patients With a Class I or IIa Indication for ICD Without an Indication for Pacing	850	Dec 2023 (extended follow-up)
NCT01085435 <sup>a</sup>	Evaluation of Factors Impacting Clinical Outcome and Cost Effectiveness of the S-ICD (The EFFORTLESS S-ICD Registry)	994	Dec 2023
NCT02787785 <sup>a</sup>	Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD)	40	Dec 2023
<b>Unpublished</b>			
NCT01736618 <sup>a</sup>	Subcutaneous Implantable Cardioverter Defibrillator System Post Approval Study (UNTOUCHED)	1766	Oct 2021
NCT00673842 <sup>a</sup>	Risk Estimation Following Infarction Noninvasive Evaluation - ICD Efficacy	1000	Dec 2021

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## Government Regulations

### National:

There is a National Coverage Determination for ICDs.<sup>104</sup> According to the most recent publication (effective February 15, 2018), CMS will cover ICDs for the following patient indications:

1. Patients with a personal history of sustained VT or cardiac arrest due to Ventricular Fibrillation (VF).
2. Patients with a prior Myocardial Infarction (MI) and a measured Left Ventricular Ejection Fraction (LVEF)  $\leq 0.30$ .
3. Patients who have severe ischemic dilated cardiomyopathy but no personal history of sustained VT or cardiac arrest due to VF, and have New York Heart Association (NYHA) Class II or III heart failure, LVEF  $\leq 35\%$ .
4. Patients who have severe non-ischemic dilated cardiomyopathy but no personal history of cardiac arrest or sustained VT, NYHA Class II or III heart failure, LVEF  $\leq 35\%$ , and been on optimal medical therapy for at least three (3) months.
5. Patients with documented familial, or genetic disorders with a high risk of life-threatening tachyarrhythmias (sustained VT or VF), to include, but not limited to, long QT syndrome or hypertrophic cardiomyopathy.

6. Patients with an existing ICD may receive an ICD replacement if it is required due to the end of battery life, Elective Replacement Indicator (ERI), or device/lead malfunction."

For each group:

1. Patients must be clinically stable (e.g., not in shock, from any etiology);
2. LVEF must be measured by echocardiography, radionuclide (nuclear medicine) imaging, cardiac Magnetic Resonance Imaging (MRI), or catheter angiography;
3. Patients must not have:
  - Significant, irreversible brain damage; or,
  - Any disease, other than cardiac disease (e.g., cancer, renal failure, liver failure) associated with a likelihood of survival less than one (1) year; or,
  - Supraventricular tachycardia such as atrial fibrillation with a poorly controlled ventricular rate

**Note: National Medicare does not specifically address the topic of subcutaneous ICDs.**

**Local:**

N/A

*(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)*

---

## Related Policies

Biventricular Pacemakers for the Treatment of Congestive Heart Failure (Retired)  
Wearable Cardioverter Defibrillators

---

## References

1. Rome BN, Kramer DB, Kesselheim AS. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. *JAMA*. Jan 2014; 311(4): 385-91. PMID 24449317
2. Food and Drug Administration. Medtronic Recalls Evera, Viva, Brava, Claria, Amplia, Compia, and Visia Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT-Ds) Due to Risk of Shortened Battery Life. April 12, 2021. <https://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-evera-viva-brava-claria-amplia-compia-and-visia-implantable-cardioverter>. Accessed April 1, 2023.
3. Food and Drug Administration. Medtronic Recalls Cobalt XT, Cobalt and Crome ICDs and CRT-Ds for Risk that Devices May Issue a Short Circuit Alert and Deliver Reduced

Energy Shock During High Voltage Therapy. August 19, 2022.

<https://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-cobalt-xt-cobalt-and-crome-icds-and-crt-ds-risk-devices-may-issue-short-circuit>. Accessed April 2, 2023.

4. Food and Drug Administration. Boston Scientific Recalls EMBLEM S-ICD Subcutaneous Electrode (Model 3501) Due to Risk of Fractures. February 10, 2021. <https://www.fda.gov/medical-devices/medical-device-recalls/boston-scientific-recalls-emblem-s-icd-subcutaneous-electrode-model-3501-due-risk-fractures>. Accessed April 3, 2023.
5. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med*. Dec 26 1996; 335(26): 1933-40. PMID 8960472
6. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*. Mar 21 2002; 346(12): 877-83. PMID 11907286
7. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. *N Engl J Med*. Nov 27 1997; 337(22): 1569-75. PMID 9371853
8. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med*. Dec 16 1999; 341(25): 1882-90. PMID 10601507
9. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med*. Jan 20 2005; 352(3): 225-37. PMID 15659722
10. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med*. Dec 09 2004; 351(24): 2481-8. PMID 15590950
11. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. *N Engl J Med*. Oct 08 2009; 361(15): 1427-36. PMID 19812399
12. Raviele A, Bongioni MG, Brignole M, et al. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta-blocker STRategy plus ICD trial. *Europace*. Jul 2005; 7(4): 327-37. PMID 16028343
13. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med*. May 20 2004; 350(21): 2151-8. PMID 15152060
14. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med*. May 20 2004; 350(21): 2140-50. PMID 15152059
15. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. *J Am Coll Cardiol*. May 21 2003; 41(10): 1707-12. PMID 12767651
16. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). *Circulation*. Mar 26 2002; 105(12): 1453-8. PMID 11914254

17. Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. *N Engl J Med*. Sep 29 2016; 375(13): 1221-30. PMID 27571011
18. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. *Heart*. Nov 2015; 101(22): 1800-6. PMID 26269413
19. Wolff G, Lin Y, Karathanos A, et al. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. *Clin Res Cardiol*. Jul 2017; 106(7): 501-513. PMID 28213711
20. Stavrakis S, Asad Z, Reynolds D. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. *J Cardiovasc Electrophysiol*. Jun 2017; 28(6): 659-665. PMID 28316104
21. Akel T, Lafferty J. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis. *Cardiovasc Ther*. Jun 2017; 35(3). PMID 28129469
22. Golwala H, Bajaj NS, Arora G, et al. Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis. *Circulation*. Jan 10 2017; 135(2): 201-203. PMID 27993908
23. Wasiak M, Tajstra M, Kosior D, et al. An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis. *Cardiol J*. 2023; 30(1): 117-124. PMID 33843044
24. Earley A, Persson R, Garlitski AC, et al. Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review. *Ann Intern Med*. Jan 21 2014; 160(2): 111-21. PMID 24592496
25. Fontenla A, Martínez-Ferrer JB, Alzueta J, et al. Incidence of arrhythmias in a large cohort of patients with current implantable cardioverter-defibrillators in Spain: results from the UMBRELLA Registry. *Europace*. Nov 2016; 18(11): 1726-1734. PMID 26705555
26. Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. *Circ Heart Fail*. Sep 01 2012; 5(5): 552-9. PMID 22821634
27. Magnusson P, Gadler F, Liv P, et al. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery. *J Cardiovasc Electrophysiol*. Oct 2015; 26(10): 1088-94. PMID 26178879
28. Horner JM, Kinoshita M, Webster TL, et al. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. *Heart Rhythm*. Nov 2010; 7(11): 1616-22. PMID 20816872
29. Hernandez-Ojeda J, Arbelo E, Borrás R, et al. Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators: Long-Term Follow-Up. *J Am Coll Cardiol*. Oct 17 2017; 70(16): 1991-2002. PMID 29025556
30. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. *J Am Coll Cardiol*. Mar 10 2015; 65(9): 879-88. PMID 25744005
31. Dores H, Reis Santos K, Adragão P, et al. Long-term prognosis of patients with Brugada syndrome and an implanted cardioverter-defibrillator. *Rev Port Cardiol*. Jun 2015; 34(6): 395-402. PMID 26028488

32. Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*. Jan 2014; 11(1): 58-66. PMID 24120999
33. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm*. Jul 2014; 11(7): 1305-23. PMID 24819193
34. Plitt A, Dorbala S, Albert MA, et al. Cardiac sarcoidosis: case report, workup, and review of the literature. *Cardiol Ther*. Dec 2013; 2(2): 181-97. PMID 25135396
35. Mantini N, Williams B, Stewart J, et al. Cardiac sarcoid: a clinician's review on how to approach the patient with cardiac sarcoid. *Clin Cardiol*. 2012; 35(7): 410-5. PMID 22499155
36. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. *J Am Coll Cardiol*. Apr 29 2008; 51(17): 1685-91. PMID 18436121
37. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. *Circulation*. Mar 1993; 87(3): 800-7. PMID 8443901
38. Alexander ME, Cecchin F, Walsh EP, et al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. *J Cardiovasc Electrophysiol*. Jan 2004; 15(1): 72-6. PMID 15028076
39. Lewandowski M, Sterlinski M, Maciag A, et al. Long-term follow-up of children and young adults treated with implantable cardioverter-defibrillator: the authors' own experience with optimal implantable cardioverter-defibrillator programming. *Europace*. Sep 2010; 12(9): 1245-50. PMID 20650939
40. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med*. Nov 27 1997; 337(22): 1576-83. PMID 9411221
41. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). *Circulation*. Aug 15 2000; 102(7): 748-54. PMID 10942742
42. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation*. Mar 21 2000; 101(11): 1297-302. PMID 10725290
43. Nademanee K, Veerakul G, Mower M, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. *Circulation*. May 06 2003; 107(17): 2221-6. PMID 12695290
44. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. *Circulation*. Apr 15 1995; 91(8): 2195-203. PMID 7697849
45. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. *J Am Coll Cardiol*. May 07 2003; 41(9): 1573-82. PMID 12742300
46. National Institute for Health and Care Excellence (NICE). Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (Review of TA95 and TA120). 2014; <https://www.nice.org.uk/guidance/ta314/documents/arrhythmias-icds-heart-failure-cardiac-resynchronisation-fad-document2>. Accessed April 3, 2023.

47. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J*. Dec 2000; 21(24): 2071-8. PMID 11102258
48. Betts TR, Sadarmin PP, Tomlinson DR, et al. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis. *Europace*. Jun 2013; 15(6): 813-9. PMID 23365069
49. Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. *J Am Coll Cardiol*. May 03 2005; 45(9): 1474-81. PMID 15862422
50. Persson R, Earley A, Garlitski AC, et al. Adverse events following implantable cardioverter defibrillator implantation: a systematic review. *J Interv Card Electrophysiol*. Aug 2014; 40(2): 191-205. PMID 24948126
51. Ezzat VA, Lee V, Ahsan S, et al. A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation?. *Open Heart*. 2015; 2(1): e000198. PMID 25745566
52. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. *Eur Heart J*. May 2014; 35(18): 1186-94. PMID 24347317
53. van Rees JB, de Bie MK, Thijssen J, et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. *J Am Coll Cardiol*. Aug 30 2011; 58(10): 995-1000. PMID 21867832
54. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. *Heart Rhythm*. Feb 2016; 13(2): 443-54. PMID 26385533
55. Food and Drug Administration. Premature Insulation Failure in Recalled Riata Implantable Cardioverter Defibrillator (ICD) Leads Manufactured by St. Jude Medical, Inc.: FDA Safety Communication. 2014; <https://wayback.archive-it.org/7993/20170722215745/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm314930.htm>. Accessed April 4, 2023.
56. Hauser RG, Katsiyannis WT, Gornick CC, et al. Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extraction. *Europace*. Mar 2010; 12(3): 395-401. PMID 19946113
57. Providência R, Kramer DB, Pimenta D, et al. Transvenous Implantable Cardioverter-Defibrillator (ICD) Lead Performance: A Meta-Analysis of Observational Studies. *J Am Heart Assoc*. Oct 30 2015; 4(11). PMID 26518666
58. Birnie DH, Parkash R, Exner DV, et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. *Circulation*. Mar 13 2012; 125(10): 1217-25. PMID 22311781
59. Hauser RG, Maisel WH, Friedman PA, et al. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management. *Circulation*. Feb 01 2011; 123(4): 358-63. PMID 21242478
60. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures:

- results from the REPLACE registry. *Circulation*. Oct 19 2010; 122(16): 1553-61. PMID 20921437
61. Ricci RP, Pignalberi C, Magris B, et al. Can we predict and prevent adverse events related to high-voltage implantable cardioverter defibrillator lead failure?. *J Interv Card Electrophysiol*. Jan 2012; 33(1): 113-21. PMID 21882010
  62. Cheng A, Wang Y, Curtis JP, et al. Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. *J Am Coll Cardiol*. Nov 09 2010; 56(20): 1651-6. PMID 21050975
  63. Faulkner BA, Traub DM, Aktas MK, et al. Time-dependent risk of Fidelis lead failure. *Am J Cardiol*. Jan 01 2010; 105(1): 95-9. PMID 20102898
  64. Smit J, Korup E, Schönheyder HC. Infections associated with permanent pacemakers and implanted cardioverter-defibrillator devices. A 10-year regional study in Denmark. *Scand J Infect Dis*. Sep 2010; 42(9): 658-64. PMID 20465488
  65. Nery PB, Fernandes R, Nair GM, et al. Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. *J Cardiovasc Electrophysiol*. Jul 2010; 21(7): 786-90. PMID 20102431
  66. Sohail MR, Hussain S, Le KY, et al. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. *J Interv Card Electrophysiol*. Aug 2011; 31(2): 171-83. PMID 21365264
  67. Borleffs CJ, Thijssen J, de Bie MK, et al. Recurrent implantable cardioverter-defibrillator replacement is associated with an increasing risk of pocket-related complications. *Pacing Clin Electrophysiol*. Aug 2010; 33(8): 1013-9. PMID 20456647
  68. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. *J Am Coll Cardiol*. Apr 08 2008; 51(14): 1357-65. PMID 18387436
  69. Tan VH, Wilton SB, Kuriachan V, et al. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. *Circ Arrhythm Electrophysiol*. Feb 2014; 7(1): 164-70. PMID 24446023
  70. Sterns LD, Meine M, Kurita T, et al. Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. *Heart Rhythm*. Jul 2016; 13(7): 1489-96. PMID 26988379
  71. Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. *Heart Rhythm*. May 2015; 12(5): 926-36. PMID 25637563
  72. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. *J Am Coll Cardiol*. Feb 23 2010; 55(8): 774-82. PMID 20170816
  73. Furniss G, Shi B, Jimenez A, et al. Cardiac troponin levels following implantable cardioverter defibrillation implantation and testing. *Europace*. Feb 2015; 17(2): 262-6. PMID 25414480
  74. Healey JS, Krahn AD, Bashir J, et al. Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations : A Randomized, Multicenter Trial. *Ann Intern Med*. Dec 2022; 175(12): 1658-1665. PMID 36343346
  75. Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. *Circulation*. Jan 05 2021; 143(1): 7-17. PMID 33073614



76. Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. *J Am Coll Cardiol.* Apr 28 2015; 65(16): 1605-1615. PMID 25908064
77. Gold MR, Aasbo JD, Weiss R, et al. Infection in patients with subcutaneous implantable cardioverter-defibrillator: Results of the S-ICD Post Approval Study. *Heart Rhythm.* Dec 2022; 19(12): 1993-2001. PMID 35944889
78. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. *Eur Heart J.* Jul 01 2014; 35(25): 1657-65. PMID 24670710
79. Olde Nordkamp LR, Brouwer TF, Barr C, et al. Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. *Int J Cardiol.* Sep 15 2015; 195: 126-33. PMID 26026928
80. Boersma L, Barr C, Knops R, et al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. *J Am Coll Cardiol.* Aug 15 2017; 70(7): 830-841. PMID 28797351
81. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. *Circulation.* Aug 27 2013; 128(9): 944-53. PMID 23979626
82. Boersma L, Burke MC, Neuzil P, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. *Heart Rhythm.* Jan 2016; 13(1): 157-64. PMID 26341604
83. Lambiase PD, Gold MR, Hood M, et al. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. *Heart Rhythm.* May 2016; 13(5): 1066-1074. PMID 26767422
84. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med.* Jul 01 2010; 363(1): 36-44. PMID 20463331
85. Theuns DA, Crozier IG, Barr CS, et al. Longevity of the Subcutaneous Implantable Defibrillator: Long-Term Follow-Up of the European Regulatory Trial Cohort. *Circ Arrhythm Electrophysiol.* Oct 2015; 8(5): 1159-63. PMID 26148819
86. Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. *J Am Coll Cardiol.* Nov 06 2012; 60(19): 1933-9. PMID 23062537
87. Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. *N Engl J Med.* Aug 06 2020; 383(6): 526-536. PMID 32757521
88. Mithani AA, Kath H, Hunter K, et al. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement. *Europace.* Feb 01 2018; 20(2): 308-314. PMID 28383717
89. Honarbakhsh S, Providencia R, Srinivasan N, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. *Int J Cardiol.* Feb 01 2017; 228: 280-285. PMID 27865198
90. Köbe J, Hucklenbroich K, Geisendörfer N, et al. Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. *Clin Res Cardiol.* May 2017; 106(5): 317-321. PMID 27878381
91. Pedersen SS, Mastenbroek MH, Carter N, et al. A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable Defibrillator System Versus a

- Transvenous System (from the EFFORTLESS S-ICD Quality of Life Substudy). *Am J Cardiol.* Aug 15 2016; 118(4): 520-6. PMID 27353211
92. Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. *J Am Coll Cardiol.* Nov 08 2016; 68(19): 2047-2055. PMID 27810043
  93. Friedman DJ, Parzynski CS, Varosy PD, et al. Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. *JAMA Cardiol.* Nov 01 2016; 1(8): 900-911. PMID 27603935
  94. Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. *Heart Rhythm.* Jan 2013; 10(1): 29-36. PMID 23032867
  95. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* May 03 2022; 145(18): e876-e894. PMID 35363500
  96. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* Dec 22 2020; 142(25): e533-e557. PMID 33215938
  97. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* Oct 02 2018; 72(14): 1677-1749. PMID 29097294
  98. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Circulation.* May 27 2008; 117(21): e350-408. PMID 18483207
  99. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* Jan 22 2013; 61(3): e6-75. PMID 23265327
  100. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm.* Nov 2019; 16(11): e301-e372. PMID 31078652
  101. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm.* Dec 2013; 10(12): 1932-63. PMID 24011539
  102. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology

- Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). *Can J Cardiol.* Oct 2014; 30(10): e1-e63. PMID 25262867
103. Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Developed in collaboration with and endorsed by the Heart Rhythm Society (HRS), the American College of Cardiology (ACC), the American Heart Association (AHA), and the Association for European Paediatric and Congenital Cardiology (AEPC) Endorsed by the Asia Pacific Heart Rhythm Society (APHRs), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhythm Society (LAHRS). *JACC Clin Electrophysiol.* Nov 2021; 7(11): 1437-1472. PMID 34794667
  104. Friedman P, Murgatroyd F, Boersma L, et al. Efficacy and safety of an extravascular implantable cardioverter defibrillator. *N Engl J Med.* 2022;387: 1292-1302.
  105. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Implantable Automatic Defibrillators (20.4). 2018; <https://www.cms.gov/Medicare-Coverage-Database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=288>. Accessed September 2023.
  106. Blue Cross Blue Shield Association. Implantable Cardioverter Defibrillator (ICD). Medical Policy Reference Manual. Policy #7.01.44, Issue 5:2017, original policy date 3/31/96, last review date June 2023.
  107. HAYES Directory Assessment. Implanted Cardioverter Defibrillators for Primary Prevention of Sudden Cardiac Death. Lansdale, PA: HAYES, Inc. December 9, 2005, Archived Jan 9, 2011.
  108. HAYES Directory Assessment. Implanted Cardioverter Defibrillators for Secondary Prevention of Sudden Cardiac Death. Lansdale, PA: HAYES, Inc. November 28, 2005, Archived December 28, 2010.
  109. HAYES Health Technology Brief. S-ICD (Subcutaneous Implantable Cardioverter Defibrillator; Boston Scientific Corp.) for Prevention of Sudden Cardiac Death. Lansdale, PA: HAYES, Inc. December 6, 2013. Updated March 2018.

*The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through September 2023, the date the research was completed.*

### Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
2/6/02	2/6/02	2/6/02	Joint medical policy established
5/7/04	5/7/04	6/15/04	Diagnosis added, current medical literature review
3/1/07	12/28/06	1/2/07	Routine maintenance
5/1/08	2/18/08	5/1/08	Maintenance new codes added, retired
11/1/12	8/21/12	8/21/12	Policy unretired; policy description, rationale, criteria and references reformatted to mirror BCBSA policy; Updated procedure codes.
11/1/13	8/20/13	9/3/13	Routine review. References updated. Removed "Automatic" from the policy title. Added new CPT category III codes (0319T-0328T) for subcutaneous implantable defibrillator system as not covered.
3/1/15	12/9/14	12/29/14	Policy status changed to reflect subcutaneous ICDs as established; Terminal T codes deleted, new CPT codes 33270-33273 added to policy as established codes. Rationale reordered, references updated.
9/1/15	6/19/15	7/16/15	Added codes 93260 and 93261 to policy, effective date of code is 1/1/15
9/1/16	6/21/16	7/25/16	Routine policy maintenance. Updated references and rationale section.
9/1/17	7/5/17	7/17/17	Policy was updated with literature review. References 14-19, 22-23, 31-40, and 71-75 were added, rationale rewritten for clarity, studies and guidelines placed in chart format. Policy statement remains unchanged.

9/1/18	6/19/18	6/19/18	Policy updated with literature review; references 25, 69, 81 and 88 added. Policy statement unchanged.
9/1/19	6/18/19		Routine policy maintenance. No change in status.
3/1/20	12/17/19		Added codes 0571T-0578T added to policy as E/I. Routine policy maintenance. No change in policy status.
1/1/21	10/20/20		Addition to MPS coverage for cardiac sarcoid with criteria. Code 0614T added as E/I.
1/1/22	10/19/21		Updated rationale, added references 2 and 73. No changes in policy status.
1/1/23	10/18/22		Rationale and supplemental sections updated, reference #21 added. No changes in policy status.
1/1/24	10/17/23		Rationale and supplemental sections updated. Substernal ICDs now addressed as E/I. Bullet added to exclusion section. No change in policy status. Vendor managed: n/a (ds)

Next Review Date: 4<sup>th</sup> Qtr. 2024

**BLUE CARE NETWORK BENEFIT COVERAGE**  
**POLICY: IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICDs), INCLUDING**  
**SUBCUTANEOUS ICDs AND SUBSTERNAL ICDs**

**I. Coverage Determination:**

<b>Commercial HMO (includes Self-Funded groups unless otherwise specified)</b>	Covered; criteria apply
<b>BCNA (Medicare Advantage)</b>	See government section.
<b>BCN65 (Medicare Complementary)</b>	Coinsurance covered if primary Medicare covers the service.

**II. Administrative Guidelines:**

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.